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Abstract 
 
This work aimed at improving efficacy and reducing toxicity of non-steroidal anti-
inflammatory (NSAIDs) and anti-bacterial drugs by designing and synthesizing mutual 
prodrugs with dual activities. The NSAIDs were ibuprofen, flurbiprofen and aspirin, which 
contained a carboxylic group as part of their structure. The antibacterial included ampicillin, 
metronidazole, isoniazid, sulfamethoxazole, sulfamerazine, sulfamethazine, sulfanilamide, 7-
ADCA and 7-AVCA, which contained an amino group as part of their structure. In the 
prodrugs of these compounds the two drugs were covalently linked together forming an 
amide linkage. In addition to these a prodrug from benzydamine, containing amino group, 
and cefazoline, containing carboxylic group was synthesized, in which the two drugs formed 
a quaternary ammonium salt. All the synthesized compounds were characterized by use of 
diverse analytical techniques including elemental analysis, FT-IR, electronic spectra, 1H and 
13C NMR, ESI-MS and single crystal XRD techniques. 
The new compounds were subjected to anti-bacterial, anti-inflammatory, enzyme inhibition 
and toxicity tests in order to evaluate them as more effective and safe drugs with dual 
activities. Some of the activity related properties, which could not be determined 
experimentally, were determined through computational analysis. The results showed that 
aspirin, flurbiprofen and ibuprofen prodrugs perform better (having moderate to significant 
difference) than the parent drugs in anti-bacterial and anti-inflammatory tests. The 
computational analysis also suggests that the prodrugs possess better druglike properties and 
bioavailability with slight variations. Thus this study clearly indicates that mutual prodrug is 
an advantageous option where a concomitant treatment is required. 
 
  
 
Table of contents 
1. Introduction ............................................................................................................................................ 5 
1.1. General ....................................................................................................................................... 5 
1.2. Prevalence of infections and Inflammation ................................................................................ 6 
1.3. Antibiotics .................................................................................................................................. 6 
1.4. Resistance to antibiotics ............................................................................................................. 8 
1.5. New generations of antibiotics ................................................................................................... 9 
1.6. Anti-inflammatory drugs ............................................................................................................ 9 
1.6.1. Steroidal anti-inflammatory drugs ........................................................................................... 10 
1.6.2. Non-steroidal anti-inflammatory drugs .................................................................................... 10 
1.7. Prodrugs ................................................................................................................................... 11 
1.7.1. Limitation of prodrug design ................................................................................................... 13 
1.8. Mutual prodrugs ....................................................................................................................... 13 
1.9. Drugs selected for present work ............................................................................................... 14 
1.9.1. NSAIDs .................................................................................................................................... 14 
1.9.2. Antibiotics ................................................................................................................................ 16 
1.10. Biological evaluation of prodrugs ............................................................................................ 21 
1.11. Anti-bacterial study .................................................................................................................. 22 
2. Experimental ........................................................................................................................................ 25 
2.1. Materials ................................................................................................................................... 25 
2.2. Chromatography ....................................................................................................................... 26 
2.3. Synthesis ................................................................................................................................... 26 
2.3.1. Cefazolin sodium-benzydamine hydrochloride HCl mutual prodrug, 3-[(1-benzyl-
1H-indazol-3-yl)-oxy]-N,N-dimethyl-propan-1-aminium3-{[(5-methyl-1,3,4-
thia-diazol-2-yl)sulfan -yl] meth-yl}-8-oxo-7-[(1H-tetra-zol-1-yl)acetamido]-5-thia-
1-aza-bicyclo-[4.2.0]octane-2-carboxylate (benzydaminium cephazolinate) (A) ................... 27 
2.3.2. Aspirin chloride, 2-(chlorocarbonyl) phenyl acetate ................................................................ 28 
2.3.3. Aspirin-sulfanilamide mutual prodrug, 2-(((4-aminophenyl) sulfonyl) carbamoyl) 
phenyl acetate (A20) ............................................................................................................... 28 
2.3.4. Synthesis of aspirin –sulfamethoxazole mutual prodrug, 2-((4-(N-(5-methylisoxazol-
3-yl) sulfamoyl) phenyl) carbamoyl) phenyl acetate (A24) .................................................... 29 
2.3.5. Synthesis of aspirin-sulfamerazine mutual prodrug, 2-((4-(N-(4-methylpyrimidin-2-
yl)sulfamoyl) phenyl) carbamoyl) phenyl acetate (A25)......................................................... 30 
2.3.6. Synthesis of ibuprofen chloride, 2-(4-isobutylphenyl) propanoyl chloride  ............................ 31 
2.3.7. Synthesis of ibuprofen-sulfamethazine mutual prodrug, N-(3-(N-(4, 6-
dimethylpyrimidin-2-yl) sulfamoyl) phenyl)-2-(4-isobutyl phenyl) propanamide 
(A2). ........................................................................................................................................ 32 
2.3.8. Synthesis of ibuprofen-sulfanilamide mutual prodrug, N-((4-aminophenyl) sulfonyl) 
-2- (4-isobutylphenyl) propanamide (A3) ............................................................................... 33 
2.3.9. Synthesis of prodrug of ibuprofen and isoniazid, N'-(2-(4-isobutylphenyl) propanoyl) 
isonicotinohydrazide (A4) ....................................................................................................... 34 
2.3.10. Synthesis of prodrug of ibuprofen and sulfamethoxazole, 2-(4-isobutylphenyl)-N-(4-
(N-(5-methylisoxazol-3-yl) sulfamoyl) phenyl) propanamide (A5) ........................................ 35 
2.3.11. Synthesis of ibuprofen and sulfamerazine, 2-(4-isobutylphenyl)-N-(4-(N-(4-
methylpyrimidin-2-yl) sulfamoyl) phenyl) propanamide” (A10) ............................................ 36 
2.3.12. Synthesis of prodrug of ibuprofen and metronidazole 2-(2-methyl-5-nitro-1H-
imidazol-1-yl) ethyl 2-(4-isobutylphenyl) propanoate (A11) .................................................. 37 
2.3.13. Synthesis of prodrug of Ibuprofen and 7-ADCA, 7-(2-(4-isobutyl 
phenyl)propanamido)-3-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-
carboxylic acid (A12). ............................................................................................................. 38 
2.3.14. Synthesis of prodrug of ibuprofen and 7-AVCA, 7-(2-(4-isobutyl phenyl) 
propanamido-8-oxo-3-vinyl-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid 
(A18) ....................................................................................................................................... 39 
  
2.3.15. Synthesis of flurbiprofen chloride, 2-(2-fluoro-[1, 1’-biphenyl]-4-yl) propanoyl 
chloride … ............................................................................................................................ 40 
2.3.16. Synthesis of prodrug of flurbiprofen and sulfanilamide, N-((4-aminophenyl) 
sulfonyl)-2-(2-fluoro-[1, 1’-biphenyl]-4-yl) propanamide (A6) ........................................... 41 
2.3.17. Synthesis of prodrug of flurbiprofen and sulfamerazine, 2-(2-fluoro-[1, 1'-
biphenyl]-4-yl)-N-(4-(N-(4-methylpyrimidin-2-yl) sulfamoyl) phenyl) 
propanamide (A7) ................................................................................................................. 42 
2.3.18. Synthesis of prodrug of flurbiprofen and sulfamethazine, N-(4 (N-(4, 6-
dimethylpyrimidin-2-yl) sulfamoyl)phenyl)-2-(2-fluoro-[1,1'-biphenyl]-4-yl) 
propanamide (A8) ................................................................................................................. 43 
2.3.19. Synthesis of flubiprofen and isoniazid, N'-(2-(2-fluoro-[1, 1’-biphenyl]-4-yl) 
propanoyl) isonicotinohydrazide (A9) .................................................................................. 44 
2.3.20. Synthesis of prodrug of flurbiprofen and metronidazole, 2-(2-methyl-5-nitro-1H-
imidazol-1-yl) ethyl 2-(2-fluoro-[1, 1'-biphenyl]-4-yl)propanoate (A13) ............................ 45 
2.3.21. Synthesis of prodrug of flurbiprofen and sulfamethoxazole, 2-(2-fluoro-[1, 1’-
biphenyl]-4-yl)-N-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl) phenyl) propanamide 
(A14) ..................................................................................................................................... 46 
2.3.22. Synthesis of prodrug of flurbiprofen and 7-ADCA, 7-(2-(2-fluoro-[1, 1’-biphenyl]-
4-yl) propanamido)-3-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-
carboxylic acid (A16). .......................................................................................................... 47 
2.3.23. Synthesis of prodrug of flurbiprofen and 7-AVCA, 7-(2-(2-fluorobiphenyl-4-yl) 
propanamido)-3-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic 
acid (A17) ............................................................................................................................. 48 
2.3.24. Synthesis of prodrug of ibuprofen and ampicillin sodium, 6-(2-(2-(4-
isobutylphenyl) propanamido)-2-phenylacetamido)-3, 3-dimethyl-7-oxo-4-thia-1-
azabicyclo [3.2.0] heptane-2-carboxylate (A1) .................................................................... 49 
2.3.25. Synthesis of prodrug of flurbiprofen and ampicillin sodium sodium 6-(2-(2-(2-
fluoro-[1, 1’-biphenyl]-4-yl) propanamido)-2-phenylacetamido)-3, 3’-dimethyl-7-
oxo-4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylate (A15) .............................................. 50 
2.4. List of successful reactions of antibiotics and anti-inflammatory drugs .................................. 51 
2.5. Characterization ........................................................................................................................ 52 
2.5.1. Melting point ............................................................................................................................ 52 
2.5.2. Spectroscopic techniques ......................................................................................................... 52 
2.6. Biological Studies ..................................................................................................................... 53 
2.6.1. Antibacterial activities  ............................................................................................................ 53 
2.6.2. Enzyme inhibition study .......................................................................................................... 56 
2.6.3. Anti-tuberculosis activity ......................................................................................................... 59 
2.6.4. Toxicity .................................................................................................................................... 61 
2.7. Computational analysis  ........................................................................................................... 62 
3. Results and Discussion ......................................................................................................................... 63 
3.1. Synthesis ................................................................................................................................... 63 
3.1.1. Synthesis of benzydaminium cefazolinate ............................................................................... 64 
3.1.2. Synthesis of aspirin prodrugs (A20, A24, A25) ....................................................................... 65 
3.1.3. Synthesis of ibuprofen prodrugs (A2, A3, A4, A5, A10, A11, A12, A18) .............................. 68 
3.1.4. Synthesis of flurbiprofen prodrugs (A6, A7, A8, A9, A13, A14, A16, A17) .......................... 74 
3.1.5. Synthesis of ibuprofen and flurbiprofen prodrugs with ampicillin (A1, A15) ......................... 79 
3.2. Biological activities .................................................................................................................. 81 
3.2.1. Enzyme inhibition studies ........................................................................................................ 85 
3.2.2. Anti-tuberculosis activity ......................................................................................................... 91 
3.2.3. Toxicity .................................................................................................................................... 92 
3.3. Computational studies ............................................................................................................ 100 
3.4. Conclusions ............................................................................................................................ 107 
4. References ......................................................................................................................................... 108 
 
  
List of figures 
Figure 1: XRD view of benzydaminium cephazolinate ........................................................... 66 
Figure 2: FTIR, H-NHR, C13-NMR and ESI-MS spectra of A11………………………...…73  
Figure3: Mycobacterial colonies in drug free tube .................................................................. 91 
Figure 4: No Mycobacterial colonies in the tube containing isoniazid ................................... 91 
Figure 5: No Mycobacterial colonies in the tube containing A4 ............................................. 92 
Figure 6: No Mycobacterial colonies in the tube containing A9 ............................................. 92 
Figure 7: Section of the liver of the mouse of control group ................................................... 96 
Figure 8: Section of the liver of mouse treated with ibuprofen ............................................... 96 
Figure 9: Section of the liver of the mouse treated with Flurbiprofen ..................................... 96 
Figure 10: Section of the liver of the mouse treated with aspirin ............................................ 97 
Figure 11: Section of the liver of moue treated with metronidazole ....................................... 97 
Figure 12: Section of the liver of mouse treated with sulfanilamide ....................................... 97 
Figure 13: Section of the liver of the mouse treated with sulfamethoxazole ........................... 98 
Figure 14: Section of the liver of the mouse treated with A5 .................................................. 98 
Figure 15: Section of the liver of the mouse treated with A6 .................................................. 98 
Figure 16: Section of the liver of the mouse treated with A11 ................................................ 99 
Figure 17: Section of the liver of the mouse treated with A13 ................................................ 99 
Figure 18: Section of the liver of the mouse treated with A14 ................................................ 99 
Figure 19: Section of the liver of the mouse treated with A20 .............................................. 100 
Figure 20: Section of the liver of the mouse treated with A24 .............................................. 100 
 
 
 
  
List of tables 
Table 1: Most commonly used drugs …... ................................................................................. 7 
Table 2: Most common infections and inflammatory responses observed in Pakistan ............. 7 
Table 3: Concentrations of antibiotics used ............................................................................. 55 
Table 4: Concentration of prodrugs used (ibuprufen) .............................................................. 55 
Table 5: Concentration of prodrugs used (flurbiprofen) .......................................................... 55 
Table 6: Concentration of prodrugs used (aspirin) .................................................................. 55 
Table 7: Antibacterial activity of standards ............................................................................. 83 
Table 8: Antibacterial activity of prodrugs .............................................................................. 84 
Table 9: Anti-Inflammatory assay - standards ......................................................................... 86 
Table 10: Anti-Inflammatory activity - prodrugs .................................................................... 86 
Table 11: Acetylcholinesterase assay of standards .................................................................. 85 
Table 12: Acetylcholinesterase assay of prodrugs ................................................................... 87 
Table 13: Butyrylcholinesterase assay of standards ................................................................ 88 
Table 14: Butyrylcholinesterase assay of prodrugs ................................................................. 88 
Table 15: DPPH activity of standards ...................................................................................... 90 
Table 16: DPPH activity of prodrugs....................................................................................... 90 
Table 17: Anti-tuberclosis activity of the standard and prodrug ............................................. 92 
Table 18: Important points regarding toxic effects in mice ..................................................... 93 
Table 19: Computational predicted physico-chemical properties of the synthesized 
prodrugs ................................................................................................................................. 102 
Table 20: Computational predicted structure related properties ............................................ 104 
Table 21: Computational predicted LogBB, LogPS and Bioavailability of A1-A25 
Studied compounds ................................................................................................................ 104 
Table 22: Computational predicted LD50 values (mg/kg) of prodrugs .................................. 106 
5 
 
1. Introduction 
1.1. General 
Generally infections are associated with some kind of inflammation; as a result it is 
standard practice to prescribe anti-infective and anti-inflammatory drugs 
concomitantly. So it is desirable to have drugs with anti-infective and anti-
inflammatory activities embodied in one molecule. Very few drugs are available 
having such a dual activity. One approach to achieve this end could be to synthetically 
combine appropriate anti-infective with anti-inflammatory molecules. Such 
combinations may provide us with the so-called mutual prodrugs for use in a single 
dose. The present work was planned to study the formation of diverse combination 
products by use of various anti-infective and anti-inflammatory agents, which may act 
as mutual prodrugs. Several studies involving synthesis of mutual prodrugs have been 
reported but there exists only a few reports describing the synthesis of prodrugs from 
anti-infective and anti-inflammatory agents. A brief review of literature in this regard 
is presented in the following paragraph. 
The mutual prodrugs, synthesized and reported in the literature, mainly focused to 
mask the free carboxylic acid group of the anti-inflammatory drugs with a view to 
improve taste or reduce ulcerogenic and hepatotoxic effects [1]. Drugs used for 
synthesizing these specific mutual prodrugs were ibuprofen, flurbiprofen, naproxen, 
diclofenac, 4-aminophenylacetic acid, 5-aminosalicylic acid among the NSAIDs, 
while sulfa drugs and other antibiotics were modified at terminal amino groups [2, 3, 
4,5]. 
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The objective of the present work was to design and synthesize mutual prodrugs 
involving various antibacterial and NSAIDs. The new compounds were expected to 
be less toxic and retain their pharmacological activity with some advanced features. 
1.2. Prevalence of infections and Inflammation  
It can be assessed through a simple survey of patients reporting to hospitals and 
general physicians that infections and inflammatory response thereof are the most 
prevalent all over the world. The NSAIDs and anti-infective enjoy about 30% share in 
drug market. Table 1 lists a pattern of drug usage [6]. 
Infection is a response of a host tissue to the attack of microorganisms on body. 
Infection can be caused by infectious agents such as viruses, prions, viroids, and 
microorganisms. Immune system of the host organisms fights against infections 
through inflammatory response. Thus inflammation is a defensive attempt to remove 
injurious stimuli and to start the healing process and itself is not a replacement of 
infection”. The most common infections resulting in inflammation (fever, pain, loss of 
function and swelling) in Pakistan are listed in Table 2. 
1.3. Antibiotics  
Antibiotics are mainly the metabolic products of microorganisms, which can inhibit 
the growth of other microorganisms or kill them [7]. They can be classified, according 
to their mechanism of action, into four types. 
i) Antibiotics which inhibit biosynthesis of bacterial cell wall” [8, 9]: 
Cephalosporins (ampicillin, 7-amino deacetoxycephalosporanic acid 7-amino-
3-vinylcephalosporanic acid, amoxicillin) [10], glycopeptides, 
lipoglycopeptides [11] and isoniazid [12] are some of the examples. 
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Table 1: Most commonly used drugs 
 
 
1: Paracetamol, 2: Salbutanol, 3: augmentin, 4: Ibuprofen, 5: Folic Acid, 6: Fluticasone, 7: 
Mometasone, 8: Azithromycine, 9: Rehydration Salt, 10: Chlorpheniramine,, 13: Symbicot 
turbuhaler, 14: Diclofenac Get, 18: cefuroxime 20: Ceftriaxone, 21: sodium Valporate 
” 
Table 2: Most common infections and inflammatory responses observed in Pakistan 
 
Infection Inflammatory 
response 
Infection Inflammatory 
response 
Respiratory tract  Skin and soft tissue  
Pharyngitis, 
laryngitis sinusitis 
Fever Boils, abscesses Swelling, irritation 
and pain 
Bronchitis Headache Diabetic foot 
infection 
Foot pain 
Pneumonia Fever + Chest pain Urinary tract    
Tuberculosis Fever + 
 Lymphadenitis 
Cystitis, urethritis Flank along with 
fever and 
abdomen pain   
ENT  Gastrointestinal tract  
Otitis Media fever, ear pain along 
with feeling of 
fullness 
Amoebic 
dysentery 
Pain in stomach 
Lose motions 
Tonsillitis Fever, Throat ache Typhoid fever Fever 
” 
 
 
 
 
  0.6 Years 
(n=775) 
7.11 Years 
(n=284) 
≥ 12Years 
(n=127) 
Male 
(n=665) 
Female 
(n=521) 
Inpatient  
(n=541) 
Outpatient  
(n=845) 
Drugs % Drug % Drug % Drug % Drug % Drug % Drug % Drug % 
1 12.6 1 15.1 2 12.3 4 7.9 1 5.5 1 13.5 1 19.8 2 8.9 
3 4.7 3 6.2 5 4.6 1 5.5 5 2.3 3 5.4 2 6.2 6 5.1 
5 3.5 9 3 4 3.5 14 3.9 4 4.2 4 4 18 3.0 7 4.5 
8 2.3 12 2.6 8 2.5 2 3.1 9 2.7 7 2.1 8 2.8 13 2.8 
10 2 8 2.3 14 2.1 17 2.4 14 2 20 3.0 10 2.1 21 2.0 
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ii) Antibiotics that inhibit protein biosynthesis [13]: Examples are: 
aminoglycoside, tetracycline, macrolides, lincosamides, streptogramins and 
oxazolidinones.” 
iii) “Antibiotics that inhibit DNA/RNA” synthesis [14,15]: These include 
quinolones and rifamycins. 
iv) Antibiotics that inhibit folate synthesis [16, 17]: Sulfonamides belong to this 
group”.  
1.4. Resistance to antibiotics  
“Antibiotics are great tools to fight infections; but their unnecessary/excessive use has 
resulted into such microorganisms which show antimicrobial resistance for the 
medicines to which originally these were sensitive. Antibiotic resistance is a serious 
and rapidly growing problem; World Health Organization has declared antibiotic 
resistant organisms as nightmare bacteria. This issue of drug resistance is getting 
serious day by day not only in developing but also developed countries. Antibiotics 
usually have a particular target and specific mode of action, thus these interact with a 
microbe similar to a lock and key model. Antibiotics bond to specific parts of 
bacteria, and either impair or kill them. A specific key (the right antibiotic molecule) 
is necessary to fit in the specific lock (a receptor molecule on the target bacterium). In 
the evolutionary competition between antimicrobials and the bacteria, the bacteria 
evolve ways of fighting back. They have natural process of occasional changes to 
their DNA. These genetic changes lead to the development of new traits, some of 
which allow the individual bacterium to counteract the effects of the antibiotic 
substance. Antibiotics, which were successfully being used for treatment of infectious 
diseases, stopped working against antibiotic resistant bacteria as result of mutation in 
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their DNA. Once the resistance develops in bacteria, these resistant species can share 
and transfer genetic information to other non-resistant bacteria, hence making them 
resistant too. As a result some "superbugs” (resistant to all available antibiotics) [18] 
have come into being.” 
1.5. New generations of antibiotics  
“As a result of this ever-increasing resistance problem in bacteria, the antibacterial 
have limited life span and the resistant drugs are being replaced with the new 
analogues, generally known as new generations.” 
The new generations of antibacterial are commonly designed by substituting different 
groups on a pharmacophore. If the substituent is another active drug, the so-called 
mutual prodrugs may be obtained. Such analogues would possess unique properties 
with less exposure of body to the unwanted substituents in the conventional prodrugs. 
New generations of different antibiotics are being synthesized through structural 
modifications. Cephalosporins of the 1st generation were effective against 
haemophilus and other Gram-positive bacteria. This was followed by development of 
2nd, 3rd and 4th generations [19]. Similarly quinolones, also, have been divided into 
generations based on their antibacterial spectrum [20]. Research on new generations is 
vital to address this new threat of getting into a post-antibacterial era.  
1.6. Anti-inflammatory drugs  
“Any chemical substance that reduces/treats inflammation is known as anti-
inflammatory drug.   Anti-inflammatory drugs can broadly be divided into two 
classes, i. e., steroidal and non-steroidal.” 
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1.6.1. Steroidal anti-inflammatory drugs 
“There are a number of steroids which can reduce inflammation or swelling by 
binding to glucocorticoid receptors [21]. These drugs are also known as 
corticosteroids. The other type, immune selective anti-inflammatory steroids, is a 
class of peptides [22]. Steroidal therapy sometimes results in irreversible adverse 
effects [23]. This problem led the medicinal chemists to discover NSAIDs [24].” 
1.6.2. Non-steroidal anti-inflammatory drugs 
“Non-steroidal anti-inflammatory drugs are non-narcotic in nature. These reduce 
inflammation along with pain by inhibiting cyclooxygenases, COX-1 and COX-2, 
[25, 26]. The COX-2 synthesizes prostaglandins, which cause inflammation, whereas, 
the COX-1 helps in platelet formation and also act on parietal cells to protect 
stomach. NSAIDs can be classified into 8 broad categories on the basis of their 
chemical structure as: i) arylacetic acid analogues, ii) hetero arylacetic acid analogues, 
iii) arylpropionic acid analogues, iv) naphthalene acetic acid analogues, v) salicylic 
acid analogues, vi) pyrazolones, vii) pyrazolodiones and viii) miscellaneous anti-
inflammatory drugs.” 
The great chemical diversity of NSAIDs yields a big range of pharmacokinetic 
characters. Although there are a number of differences in the kinetics of NSAIDs yet 
there are some common properties. All of the NSAIDs with few exceptions 
(Naphthalene acetic acid derivative) are weak organic acids.” 
1.7. Drug interactions 
Co-administration of the two different types of drugs has resulted in surprising and 
unpredicted effects in the patients. This is probably due to altered pharmacokinetics of 
11 
 
the one or both the drugs [27]. These interactions are commonly referred to as drug 
interactions [28, 29, 30, 31, 32, 33, 34]. What makes it worse is the large numbers of 
drugs that are being introduced every year and thus new interactions are increasingly 
reported. Such interactions may suppress the effectiveness of one of the two drugs, 
cause unexpected side effects [35, 36] or increase the action of a particular drug [37, 
38, 39, 40, 41] so these can be synergistic (where the drug’s action is increased) or 
antagonistic (when the drug’s action is decreased [42, 43] or a completely new effect 
may be produced that neither produces on its own. [44, 45]. Some drug interactions 
can even be harmful .These drug interactions may occur out of any accidental misuse 
of medicines due to lack of knowledge about the active ingredients [46, 47]. These 
processes may include alterations in the pharmacokinetics of the drug [48 ,49 ,50, 51, 
52] such as alterations in the absorption, distribution, metabolism, and excretion of a 
drug [53, 54, 55, 56]. These may be classified as chemical and biological interactions 
[57]. 
1.8. Prodrugs 
“Prodrugs are the attempts towards decreased toxicity and improved bioavailability in 
drugs. These are apparently inactive molecules by themselves and produce active 
metabolites in the body. In prodrugs, an enzymatic or a chemical transformation is 
required to release an active drug. Prodrugs are generally designed to make the 
intended drug safer with increased solubility to enhance oral bioavailability, 
decreased toxicity, improved chemical stability, avoid premature metabolism, 
adequate tissue penetration and to improve taste [58]. The key role of a prodrug is to 
mask a polar functional group (XH) where X can be OH, COOH, SH, and NH 
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in a transient manner so that once the prodrug is on the target site, it hydrolyses to 
release the active drug molecule [59].” 
The prodrug approach in drug design is relatively a new and versatile method, applied 
to a wide range of drug formulations. However, for prodrug strategies to be 
successful, analysis of parent drug properties and the proper identification of possible 
barriers are important. Clinically, the majority of prodrugs are used with the aim of 
enhancing drug permeation by increasing lipophilicity. Prodrugs provide 
opportunities to overcome problems to drug formulation and delivery such as 
chemical instability, insufficient oral absorption, poor aqueous solubility, lack of site 
specificity, rapid pre-systemic metabolism, inadequate brain penetration, toxicity and 
local irritation [60]. Various prodrugs have been designed and developed to overcome 
various barriers to drug utilization [61, 62].” 
The prodrugs are designed in a way to directly attach the intended drug to a carrier 
group. Prodrugs can also be attached to the carrier group through a linking group. An 
ideal prodrug should possess following properties [63].” 
i) Pharmacological inertness;  
ii) Rapid transformation into the active form at the target site;”  
iii) Non-toxic metabolic fragments followed by their rapid elimination”. 
Additional benefits of prodrugs thus include: additional biological action; improved 
pharmacokinetics [64]; reduced side effects [65, 66, 67, 68]; increased bioavailability 
[69]; better stability [70]; reduction in dose and  synergistic effect [71]. 
Prodrug approach has been a preferred research area amongst the drug design 
scientists in last decade. This area has a wide range of applications [72, 73, 74]. 
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Prodrug of NSAIDs [75, 76, 77, 78, 79, 80, 81, 82, 83] and antibiotics [84] have been 
reported. But there are only a few reports of synthesis of mutual prodrugs.  
1.9. Limitation of prodrug design  
Prodrug design has proven extremely valuable in overcoming various undesirable 
properties of drugs. On the other side, it can also give rise to a large number of newer 
difficulties, mainly in the assessment of pharmacological, pharmacokinetic, 
toxicological and clinical properties of prodrugs [85]. Ideally, the design of a suitable 
prodrug structure should be considered at the early steps of preclinical development, 
keeping in mind that prodrugs can alter the tissue distribution, bioavailability, efficacy 
and the toxicity of the parent drug. Several important elements should be carefully 
examined while designing a prodrug structure. The absorption, distribution, 
metabolism, excretion and pharmacokinetic properties need to be comprehensively 
understood [86].” 
1.10. Mutual prodrugs  
In this class of prodrug, prodrug consists of two pharmacologically active molecules 
can be attached together where each acts as a promoiety for the other and vice versa 
[87,88]. A mutual prodrug is a bipartite or tripartite prodrug in which the carrier is a 
synergistic drug to the intended drug. Benorylate is a mutual prodrug of aspirin and 
paracetamol. A prodrug relies upon change within the body to deliver the parent 
active drug to produce its pharmacological effect. The major drawback of the prodrug 
approach is the promoiety, which is basically an unwanted part, which when released 
can result in adverse effects. The term prodrug/co-drug refers to two or even more 
therapeutic compounds active against the same or different diseases and are bonded 
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through a covalent chemical linkage. Advantages include synergistic modulation of 
the process, enhancement of drug delivery, pharmacokinetic properties and the 
potential to enhance stability by masking labile functional groups. The amount of 
published work on co-drugs is limited but the available data suggest the mutual 
prodrug concept could provide a significant therapeutic improvement in 
dermatological diseases.” 
1.11. Drugs selected for present work  
1.11.1. NSAIDs  
Most commonly used NSAIDs including ibuprofen, flurbiprofen, aspirin and 
benzydamine hydrochloride were selected for this work. 
Ibuprofen 
Ibuprofen, 2-(4-isobutylphenyl) propionic acid, is a phenyl propionic acid (structure 
given below) and is in use for relieving pain  (muscle ache, headache, toothache and 
backache), common cold, soreness, swelling and stiffness caused by arthritis [89]. 
Ibuprofen is also used to reduce fever and inflammation. It is most frequently 
prescribed NSAID. In lower dose, it works as a non-narcotic analgesic.” It is soluble 
in methanol, dimethyl sulfoxide and dichloromethane  
  
Ibuprofen 
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Flurbiprofen 
Flurbiprofen, 2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanoic acid (structure given below) 
is a propionic acid. It is not only available as oral medicine but also as a topical 
ophthalmic formulation [90]. Flurbiprofen is effective intravenously for preoperative 
analgesia in minor surgery (neck, ear and nose) and also in treatment of sore throat. It 
is soluble in acetonitrile and dimethyl sulfoxide. 
 
Flurbiprofen 
Ibuprofen and Flurbiprofen both have gained acceptance in the treatment of 
osteoarthritis [91]. These are well absorbed on oral administration, undergo hepatic 
metabolism and excreted through kidney. 
Aspirin 
The most commonly employed NSAID, aspirin, 2-acetoxybenzoic acid (structure 
given below), is the prototype of the NSAIDs. Aspirin was officially approved by 
FDA in 1939. This is the standard anti-inflammatory drug for all other NSAIDs. It is a 
weak organic acid and is unique among the other NSAIDs as it irreversibly acetylates 
cyclooxygenase. Aspirin has not only anti-inflammatory but also antipyretic and 
analgesic effect. It has three therapeutic actions and these are reducing inflammation, 
pain and fever. This mainly works by inhibiting prostaglandin synthesis and is famous 
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for its anti-platelet effect as well [92]. It is soluble in methanol, ethanol, dimethyl 
sulfoxide and acetone. 
 
Aspirin 
Benzydamine 
Benzydamine, 3-(1-benzyl-1H-indazol-3-yloxy)-N,N-dimethylpropan-1-amine 
(structure given below), exists as the hydrochloride. This is a locally-acting NSAID 
with analgesic and anaesthetic characteristics for relieving pain. This is also used for 
the treatment of mouth and throat inflammation. This is soluble in water. 
 
Benzydamine 
1.11.2. Antibiotics  
Following antibiotic were selected for present studies. 
Ampicillin sodium  
Ampicillin, sodium 6-(2-(amino (phenyl) methyl) allyl)-3, 3-dimethyl-7-oxo-4-thia-1-
azabicyclo [3.2.0] heptane-2-carboxylate (structure given below), is a β-lactam 
antibiotic and is member of aminopenicillin family. It is effective against Gram-
17 
 
positive and many Gram-negative bacteria. Amino group of its structure makes it 
different from other antibiotics of the penicillin group. This amino group helps 
ampicillin to penetrate outer membrane of the gram-negative bacteria. It is soluble in 
water. 
 
Ampicillin sodium 
Cefazolin sodium 
Cefazolin sodium, sodium 7-(2-(1H-tetrazol-1-yl)acetamido)-3-(((5-methyl-1,3,4-
thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 
(structure given below), is a 1st generation cephalosporin antibiotic. It is commonly 
used to treat infections of the bone, joint, lung, heart valve, blood, urinary tract, 
stomach, and especially skin. It is soluble in water. 
 
Cefazolin sodium 
18 
 
7-ADCA 
7-ADCA, 7-amino deacetoxycephalosporanic acid (structure given below), belongs to 
the β-Lactam group and it is one of the building blocks of cephalosporin antibiotics. It 
is precursor of cephalexin and ampicillin. It is soluble in dimethylformamide. 
 
7-ADCA 
7-AVCA 
7-AVCA, 7-amino-3-vinylcephalosporanic acid (structure given below), is member of 
β-lactam group and it is a precursor of cefdinir and cefixime. It is soluble in 
dimethylformamide. 
 
7-AVCA 
Sulfamirazine  
Sulfamerazine, 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide (structure 
given below), is used as an antibiotic. This antibiotic can be used to treat bronchitis, 
urinary tract infections and prostatitis. This is a sulfonamide drug and inhibits 
bacterial synthesis of dihydrofolate (an enzyme involved in folate synthesis in 
bacteria). It is soluble in dichloromethane and dimethyl sulfoxide. 
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Sulfamirazine 
Sulfamethazine  
Sulfamethazine, 4-(((4,6-dimethylpyrimidin-2-yl)methyl)sulfonyl)aniline (structure 
given below), belongs to sulfonamides. It is commonly used for the treatment of 
bronchitis, urinary tract infections and prostatitis. Mechanism of action is similar to 
sulfamerazine. It is soluble in dichloromethane. 
 
Sulfamethazine 
Sulfanilamide  
Sulfanilamide, 4-aminobenzenesulfonamide (structure given below), is an antibiotic 
with a molecule containing sulfonamide functional group. It can be used for the 
treatment of vulvovaginitis, an infection by Candida albicans. It inhibits an important 
bacterial enzyme dihydropteroate synthetase, necessary for the synthesis of folic acid, 
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without it bacteria cannot survive. It is soluble in dichloromethane and dimethyl 
sulfoxide 
 
Sulfanilamide 
Sulfamethoxazole  
Sulfamethoxazole, 4-amino-N-(5-methylisoxazol-3-yl) benzenesulfonamide (structure 
given below), is a bacteriostatic antibacterial agent that inhibits folic acid synthesis in 
the susceptible bacteria. It can be used for the treatment of bacterial infections 
resulting in bronchitis, pneumonia, prostatitis, middle ear and urinary tract infections. 
It is soluble in methanol, ethanol and dichloromethane. 
 
Sulfamethoxazole 
Metronidazole 
Metronidazole, 2-(2-methyl-5-nitro-1H-imidazol-1-yl) ethanol (structure given 
below), is a synthetic antibacterial as well as antiprotozoal agent of the nitroimidazole 
class. Metronidazole is exceptionally effective against many anaerobic bacterial 
infections. It is soluble in ethanol and dimethyl sulfoxide. 
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Metronidazole 
Isoniazid  
“Isoniazid, isonicotinohydrazide (structure given below), is an antibacterial agent 
(nicotinamide derivative) that primarily acts as a tuberculostatic. It inhibits the 
synthesis of nucleic acids, lipids, and mycolic acid of the cell walls of bacteria 
belonging to genus Mycobacterium, especially M. tuberculosis. It is soluble in 
methanol, acetone and dimethyl sulfoxide.” 
 
Isoniazid 
1.12. Biological evaluation of prodrugs  
Drugs can be assessed on their biological activities. As antibiotics and anti-
inflammatory drugs are the main focus of the present study so prodrugs synthesized 
from these drugs should be at least monitored for their parent basic properties. 
Biological properties can be studied in vitro, in vivo or through computational 
analysis. A key benefit of in vitro work is to permit a great level of convenience and 
simplification in the system under study. Computational studies can be used to point 
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toward “performed on the computer or via computer simulation”. Several software are 
available for this purpose [93].   
1.12.1. Anti-bacterial study 
There is usually no single complete bioassay available to evaluate the antimicrobial 
activity of a drug. Hence, the antibacterial evaluation process usually involves the use 
of more than one bioassay methods then careful assessment and comparison of all the 
observed data in order to obtain an appropriate conclusion [94]. Antimicrobial activity 
can be measured by following methods. 
a) Agar dilution method [95] 
b) Bio autographic method [96]  
c) Agar diffusion method [97, 98] 
In the present study, agar diffusion method was used in antibacterial activity while 
agar dilution method was used in anti-tuberculosis activity. In agar diffusion method, 
wells are usually cut in seeded agar and the sample is then introduced directly into 
these wells while in agar dilution method the medium is inoculated with the test 
organism and the samples to be tested are mixed with the inoculated medium. 
1.12.2. Enzyme inhibition assay 
Enzyme assay are the laboratory methods used for measuring enzymatic activity 
(enzyme inhibition and enzyme kinetics). Enzyme assays can be categorised as 
continuous assays and discontinuous assays. In present study, continuous 
spectrophotometric assay type was selected. In this type, course of the reaction was 
followed by measuring change in light absorption of the assay solution. In this study, 
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5-lipoxygenase (5-LOX), acetylcholinesterase (AChE), butyrylcholinesterase (BChE) 
and α-chymotrypsin were the enzymes selected for the enzyme inhibition assays. 
5-LOX is an enzyme that in human beings is encoded by ALOX5 gene. This enzyme 
transforms essential fatty acids into leukotrienes (eicosanoid inflammatory mediators 
produced in white blood cells). Leukotrienes are produced in leukocytes (white blood 
cells) by the oxidation of an essential fatty acid arachidonic acid by 5-LOX [99]. 
Inhibiting 5-LOX blocks the biosynthesis of harmful inflammatory leukotrienes [100]. 
Acetylcholinesterase is an enzyme that hydrolyses neurotransmitter acetylcholine 
while butyrylcholinesterase is a non-specific cholinesterase enzyme that hydrolyses 
many different choline esters. BChE is very similar to the neuronal AChE. The term 
"serum cholinesterase" is generally used for these two enzymes. Assay of 
butyrylcholinesterase activity in plasma can be used as a liver function test as both 
hypercholinesterasemia and hypocholinesterasemia indicate pathological processes in 
liver. Both of these enzymes play role in increasing Alzheimer’s disease. There are 
evidences that anti-inflammatory therapies proved helpful in slowing the onset of the 
Alzheimer's disease. Derivatives of NSAIDs have been used successfully in the search 
for multifunctional anti-Alzheimer's disease agents with good safety [101].  
1.12.3. Toxicity of NSAIDs 
All drugs are considered toxic at some level; the level of toxicity can be observed by 
drug’s effects on the target which may be an organism, organ, tissue or a cell. 
Toxicity can be acute, sub chronic or chronic in nature depending upon the exposure 
of the target to the drug.  Major challenge in drug discovery is to find a margin 
between efficacy and toxicities, enough to provide clinical benefits to patients while 
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avoiding to put them at unnecessary risk of side effects. Drugs like NSAIDs and 
antibiotics may cause gastrointestinal and hepatic toxicity [102,103]. 
The most pronounced and fatal adverse effect of NSAIDs is on gastrointestinal tract 
(GIT). The GIT toxic effects include dyspepsia, ulcers and bleeding [104]. Around 30 
million people world over consume these drugs on daily basis [105] and about 30% of 
these users may develop GIT toxicity. It has also been estimated that about one third 
of the arthritis patients are victims of these adverse effects. A careful survey indicated 
that approximately 0.1 million patients are hospitalized annually for NSAID-related 
GIT complications. This indicates that the deaths exceed than those by AIDS and 
cervical cancer [106]. Apparently these toxic effects are due to presence of carboxylic 
acid moiety in most of the NSAIDs. This alarming situation warrants structural 
modification(s) in existing NSAIDs where these effects can be avoided by 
sequestering the carboxylic group. In order to achieve this, different strategies have 
been adopted in modifying the existing NSAIDs [107] or synthesizing new molecules 
[108]. One of the objectives of the present work was to derivatize some of the 
NSAIDs with other drug molecules, having amino group in them, through amide 
formation. This type of derivatization would afford prodrugs with dual effect with 
elimination of toxic effects due to free carboxylic groups in NSAIDs. 
Mutual prodrugs can be used to decrease toxic and adverse effects while increasing 
the pharmacological effects. 
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2. Experimental 
2.1. Materials 
The drugs used were: cefazolin Sodium (GlaxoSmithKline, Karachi), ampicillin 
(Sigma-Aldrich, Germany), sulfamethoxazole (Sigma-Aldrich, Germany),   
sulfamethazine (Sigma-Aldrich, Germany), sulfamerazine (Sigma-Aldrich, Germany), 
sulfanilamide (Sigma-Aldrich, Germany), isoniazid (Sigma-Aldrich, Germany), 7-
aminodesacetoxycephalosporanic acid (7-ADCA) ( Pharmagen, Lahore), 7-amino-3-
vinylcephalosporanic acid (7-AVCA) (Pharmagen, Lahore), metronidazole 
(Nawabsons, Lahore), ibuprofen (Nawabsons, Lahore), flurbiprofen (Nawabsons, 
Lahore), benzydamine hydrochloride (Adamjee, Karachi), and aspirin (Sigma-
Aldrich, Germany). 
Dichloromethane, N, N´-dimethylformamide (DMF), triethyl amine, 4-
dimethylaminopyridine (DMAP), N, N’-dicyclohexylcarbodiimide (DCCI), 
acetonitrile, petroleum ether, methanol, diethyl ether, oxalyl chloride were of 
analytical grade from E. Merck, Germany.   
All other chemicals used in the experiments were of analytical grade and were used 
without further purification or specified otherwise. The solvents used were purified by 
distillation and dried before use. Glassware used for the reactions was oven dried. 
Round bottom used were fitted with rubber septa. Reactions were conducted under a 
positive pressure of nitrogen. Cannulae were used to transfer moisture sensitive 
liquids. 
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2.2. Chromatography  
Flash chromatography was performed using silica gel grade 9385 (Si, 230-400 mesh, 
pore size 60 Å, Sigma Aldrich) under nitrogen. Column taken was 46 cm long with 30 
mm diameter. Purity of the prodrugs was monitored on pre-coated silica gel GF-254 
(dimensions 20×20 cm 0.5 mm thick) (Merck) thin layer chromatography plates. TLC 
plates were visualised by exposure to UV light. While performing these 
chromatographic procedures, different solvent systems of low, medium and high 
polarity were used according to the requirement. 
2.3. Synthesis 
Three methods were used for synthesis of mutual prodrugs of antibiotics and 
NSAIDs. In the first method, the antibiotics and NSAIDs were mixed together in an 
appropriate solvent in equvimolar quantities and stirred at ambient temperature or 
refluxed. By this method only the reaction between cefazolin sodium and 
benzydamine hydrochloride was successful. In the second method, the NSAIDs 
containing carboxylic groups were converted to their acid chlorides by use of thionyl 
chloride or oxalyl chloride. The acid chlorides thus obtained were allowed to react 
with the antibiotics containing amino or hydroxyl groups.  With the use of thionyl 
chloride, aspirin could be coupled with sulfamethoxazole, sulfamethazine and 
sulfanilamide. With the use of oxalyl chloride the acid chlorides of ibuprofen and 
flurbiprofen could be coupled with sulfamethazine, sulfamerazine, sulfamethoxazole, 
sulfanilamide, metronidazole, isoniazid, 7-ADCA and 7-AVCA. In the third method, 
NSAIDs and antibiotics were allowed to react with each other in the presence the 
coupling agent, DCCI, and the catalyst, DMAP. By this method ampicillin could be 
coupled with ibuprofen and flurbiprofen. 
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2.3.1. Cefazolin sodium-benzydamine hydrochloride HCl mutual prodrug, 3-
[(1-benzyl-1H-indazol-3-yl)-oxy]-N,N-dimethyl-propan-1-aminium3-{[(5-
methyl-1,3,4-thia-diazol-2-yl)sulfan -yl] meth-yl}-8-oxo-7-[(1H-tetra-zol-1-
yl)acetamido]-5-thia-1-aza-bicyclo-[4.2.0]octane-2-carboxylate 
(benzydaminium cephazolinate) (A) 
Cefazolin and benzydamine HCl were coupled according to a reported method [109] 
Cefazolin (47.6 mg, 10 mmol) and benzydamine hydrochloride (34.5 mg, 10 mmol) 
were dissolved in distilled water (10 mL) separately and mixed together and stirred 
briefly. The mixture was left at room temperature for 24 h. The product crystallized 
on standing, which was isolated by filtration and dried in air at room temperature. The 
product produced a single spot on thin layer chromatographic plate (pre-coated silica 
gel GF-254 0.5 mm thick, Merck; 1:1 water-methanol); CHNS calculated 
(C34H39N11OS3): C, 52.49; H, 5.05; N, 19.81; O, 10.28; S, 12.37; found: C, 52.51; H, 
4.92; N, 19.79; O, 10.29; S, 12.31 
 
(A) 
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2.3.2. Aspirin chloride, 2-(chlorocarbonyl) phenyl acetate [110] 
 
Aspirin (180.0 mg, 1.0 mmol) was dissolved in toluene (20 mL) under nitrogen cover. 
To this aspirin solution, thionyl chloride (l mL) and catalytic amount (0.01 mL) of N, 
N´-dimethylformamide was added. The mixture was heated under nitrogen cover at 
70 oC for 1 h (the completion of reaction was monitored by TLC (pre-coated silica gel 
GF-254 0.5 mm thick, Merck; 1:2chloroform: ethyl acetate). The solvent was 
removed under reduced pressure to obtain aspirin chloride as white crystals. 1H-NMR: 
7.45-7.82 (m, 4H,H-3ʹ, H-4ʹ, H-5ʹ,H-6ʹ), 2.28 (s, 3H,  CH3-8ʹ); 13C-NMR: 169.0 (C-
7ʹ), 167.9 (C-1), 155.1 (C-1ʹ), 135.7 (C- 5ʹ), 131.6 (C-3ʹ), 128.1 (C-2ʹ), 125.8(C-4ʹ), 
120.3 (C-6ʹ), 20.3 (C-8ʹ). 
 
2.3.3. Aspirin-sulfanilamide mutual prodrug, 2-(((4-aminophenyl) sulfonyl) 
carbamoyl) phenyl acetate (A20) 
The aspirin chloride was coupled with sulfanilamide according to a reported method 
[111]. To a solution of sulfanilamide (138 mg, 0.80 mmol) in dry dichloromethane 
(15 mL) triethyl amine (0.3 mL) was added under inert atmosphere. This was 
followed by addition of aspirin chloride (159 mg, 0.80 mmol) and DMAP (12 mg, 
0.098 mmol) in dry dichloromethane (15 mL). The reaction mixture was stirred 
overnight. After this time the reaction was found to be complete as evidenced by no 
further change in TLC (pre-coated silica gel GF-254, Merck; 1:1 ethyl acetate: 
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petroleum ether) pattern. The solvent was evaporated to about one fourth of the 
volume by rotary evaporator. A white powder was isolated by filtration. The product 
was purified by column chromatography (Silca gel, 1:1 ethyl acetate: petroleum 
ether). The product (A20) was dried under reduced pressure. Yield: 153 mg (66.5%) ; 
λ max: 270 nm; IR (KBr, cm-1): 3473 (ArNH), 3230 (NHCO), 1697 (C=O amide), 
1597 (NH), 1330 (CN), 1240 (COC), 1147 (S=O), 839 (Ar); 1H-NMR 
CDCl3(δ); 7.8 (br, s., 1H, CONH), 7.58 (dd, J=8, 2.4 Hz, 2H, H-2), 7.3-7.6 (m, 4H, 
H-3ʹ, H-4ʹ, H-5ʹ, H-6ʹ), 6.65 (dd, J=8.1, 2.9 Hz, 2H, H-3, H-5), 5.4 (s, 2H), 2.0 (s, 3H, 
CH3); 
13C-NMR (δ): 173.1(C-7ʹ), 160.8 (C-1ʹʹ), 154.0 (C-4), 152.3 (C-1ʹ), 133.3 (C-
5ʹ), 130.76 (C-1), 128.7 (C-2), 124.5 (C-3ʹ), 115.1 (C-2ʹ), 113.38 (C-6ʹ), 112.9 (C-3), 
19.9 (C-8ʹ);  ESI-MS: 333.0551, [M-H+] 334.0547; C15H14N2O5S. 
 
(A20)  
2.3.4. Synthesis of aspirin –sulfamethoxazole mutual prodrug, 2-((4-(N-(5-
methylisoxazol-3-yl) sulfamoyl) phenyl) carbamoyl) phenyl acetate 
(A24) 
This compound was synthesized as per procedure for A20 above by replacing 
sulfanilamide with sulfamethoxazole (202 mg, 0.80 mmol). The purified product 
(A24) was then characterized. Yield:185mg (64%) ; λ max : 278 nm; 1H-NMR CDCl3 
(δ); 7.8 (br. S., 1H, CONH), 7.46 (dd, J=7.8, 2.2 Hz, 2H, H-3ʹ, H-5ʹ), 7.43 (dd, 7.8, 
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2.1 Hz, 2H, H-2ʹ, H-6ʹ), 7.20-7.40 (m, 4H, H-3ʹʹʹ, H-4ʹʹʹ, H-5ʹʹʹ, H-6ʹʹʹ), 6.7 (s, 1H, 
NH), 6.2 (s, 1H, H-4), 2.2 (s, 3H, H-6), 2.0 (s, 3H, H-8ʹʹʹ); 13C-NMR (δ): ;176.7 (C-
3), 173.4 (C-7ʹʹʹ), 171.1 (C-5), 160.9 (C-1ʹʹ), 150.8 (C-1ʹʹʹ), 140.9 (C-1ʹ), 133 (C-5ʹʹʹ), 
128.1 (C-3ʹ), 127.7 (C-4ʹʹʹ), 123.4 (C-3ʹʹʹ), 115.1 (C-2ʹʹʹ), 114.9 (C-6ʹʹʹ), 106.5 (C-2ʹ), 
90.0 (C-4), 18.2 (C-8ʹʹʹ), 12.4 (C-6);  ESI-MS: 416.0736 [M+H+], 415.0739; 
C19H17N3O6S. 
 
      (A24) 
2.3.5. Synthesis of aspirin-sulfamerazine mutual prodrug, 2-((4-(N-(4-
methylpyrimidin-2-yl)sulfamoyl) phenyl) carbamoyl) phenyl acetate 
(A25). 
This compound was synthesized as per procedure for A20 above by replacing 
sulfanilamide with sulfamerazine (211 mg, 0.80 mmol). The purified product (A25) 
was then characterized. Yield: 203mg (68.35%) ; λ max : 278 nm; FT-IR (KBr) ν cm-1: 
3182 (NHCO), 1683 (C=O amide), 1589 (NH), 1323 (CN), 1153 (S=O), 752 
(Ar), 698 (pyrimidine); 1H-NMR, CDCl3, TMS reference, MHz: (δ); 8.2 (s, 1H, 
CONH), 8.1 (s, 1H, CONH), 7.65 (dd, J=8.1, 2.4 Hz, 2H, H-2ʹ, H-6ʹ), 7.33 (dd, 
J=8.1, 2.1 Hz, 2H, H-3ʹ), 7.25-7.55 (m, 4H, H-3ʹʹʹ, H-4ʹʹʹ, H5ʹʹʹ, H-6ʹʹʹ), 6.75 (d, J=7.9 
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Hz, 1H, H-5), 5.16 (d, J=7.9 Hz, 1H, H-6), 2.38 (s, 3H, H-7), 2.2 (s, 3H, H-8ʹʹʹ); 13C-
NMR (ppm): 173.4 (C-7ʹʹʹ), 160.96 (C-1ʹʹ), 158.4 (C-6), 150.8 (C-2), 140.9 (C-1ʹ), 
140.8 (C-4ʹ), 133.0 (C-5ʹʹʹ), 128.1 (C-5ʹ), 127.8 (C-4ʹʹʹ), 123.4 (C-3ʹʹʹ), 115.1 (C-2ʹʹʹ), 
114.9 (C-5), 106.5 (C-2ʹ), 18.22 (C-7), 14.6 (C-8ʹʹʹ); ESI-MS: 427.0896 [M+H+], 
426.0897; C20H18N4O5S. 
 
(A25) 
2.3.6. Synthesis of ibuprofen chloride, 2-(4-isobutylphenyl) propanoyl 
chloride [112] 
Ibuprofen (1.5000 g, 7.28 mmol) was dissolved in dry dichloromethane (30 mL). To 
this dry DMF (0.03 mL) was added as catalyst. This was followed by drop wise 
addition of oxalyl chloride (3 mL) as the chlorinating agent; during the addition 
temperature was maintained at 0-5 ºC. The resulting mixture was stirred for 12 h at 
about 25ºC. After this the solvent was evaporated on a rotary evaporator. An oily 
product was obtained. 1H-NMR CDCl3(δ); 7.24 (dd, J=7.2, 1.9 Hz, 2H, H-2ʹ, H-6ʹ), 
7.14 (dd, J=7.3, 2.0 Hz, 2H, H-3ʹ, H-5ʹ), 3.81 (q, J=7.4 Hz, 1H, H-2), 2.48 (d, J=7.4 
Hz, 2H, H-7ʹ), 1.87 (m, 1H, H-8ʹ), 1.54 (d, J=7.0 Hz, 3H, H-3), 0.91 (d, J=6.7 Hz, 6H, 
H-3``); 13C-NMR: 173.6 (C-1), 140.3 (C-4ʹ), 133.1 (C-1ʹ), 129.0 (C-5ʹ), 128.7 (C-6ʹ), 
55.7 (C-2), 44.5 (C-7ʹ), 29.0 (C-8ʹ), 22.8 (C-9ʹ), 16.4 (C-3). 
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Ibuprofen chloride 
2.3.7. Synthesis of ibuprofen-sulfamethazine mutual prodrug, N-(3-(N-(4, 6-
dimethylpyrimidin-2-yl) sulfamoyl) phenyl)-2-(4-isobutyl phenyl) 
propanamide (A2). 
This compound was synthesized as per procedure for A20 above by replacing 
sulfanilamide with sulfamethazine (222.4 mg, 0.80 mmol) and aspirin chloride by 
ibuprofen chloride (180 mg, 0.80 mmol). The purified product (A2) was then 
characterized. Yield: 243.4 mg (64.9%); λ max = 290 nm; IR (KBr) ν cm-1: 3334  
(NH), 1708 (C=O), 1583 (NH), 1519 (CH), 1153 (CN); 1H-NMR CDCl3(δ); 
8.2 (s, 1H, CONH), 7.77 (m, 1H, H-4ʹ), 7.7 (m, 1H, H-5ʹ), 7.53, (s, 1H, H-5), 7.30 
(d, J=2.1Hz, 1H, H-2ʹ), 7.19 (dd, J=7.9, 2.5 Hz, 2H, H-2ʹʹʹ), 7.10 (m, 1H, H-6ʹ), 7.06 
(dd, J=7.9, 2.2 Hz, 2H, H-3ʹʹʹ, H-5ʹʹʹ), 4.2 (s, 1H, CONH), 3.65 (q, J=7.0Hz, 1H, H-
2ʹʹ), 2.25(s, 6H, H-7, H-8), 2.40 (d, J=6.8Hz, 2H, H-7ʹʹʹ), 1.8 (m, 1H, H-8ʹʹʹ), 1.5 (d, 
J=7.0 Hz, 3H, H-3ʹʹ), 0.85 (d, J=6.6 Hz, 6H, H-9ʹʹʹ, H-10ʹʹʹ); 13C-NMR (δ): 172.2 (C-
1ʹʹ), 169.5 (C-4), 169.1 (C-6), 153.2 (C-2), 144.6 (C-1ʹ), 139.4 (C-1ʹʹʹ), 135.5 (C-3ʹ), 
131.2 (C-5ʹ), 130.9 (C-4ʹʹʹ),  129.1 (C-3ʹʹʹ), 125.5 (C-6ʹʹʹ), 123.3 (C-4ʹ), 118.1 (C-6ʹ), 
115.5 (C-2ʹ), 107.9 (C-5), 52.1 (C-2ʹʹ), 44.4 (C-7ʹʹʹ), 30.4 (C-8ʹʹʹ), 22.1 (C-9ʹʹʹ, C-10ʹʹʹ), 
18.6 (C-3ʹʹ); ESI-MS: 467.2111 [M+H+]; 466.2110; C25H30N4O3S. 
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(A2) 
2.3.8. Synthesis of ibuprofen-sulfanilamide mutual prodrug, N-((4-
aminophenyl) sulfonyl) -2- (4-isobutylphenyl) propanamide (A3) 
This compound was synthesized as per procedure for A20 above by replacing aspirin 
chloride with ibuprofen chloride (180 mg, 0.80 mmol). The purified product (A3) was 
then characterized. Yield: 206 mg (71%) ; IR (KBr) ν cm-1: 3475 (NH), 3329 
(amide), 1720 (C=O), 1602 (C=C), 1484 (CH), 850 (Ar); 1H-NMR CDCl3(δ); 
7.45 (dd, J=7.9, 2.1 Hz, 2H, H-2), 7.19 (dd, J=7.9, 2.5 Hz, 2H, H-2ʹʹ, H-6ʹʹ), 7.06 (dd, 
J=7.9, 2.2 Hz, 2H, H-3ʹʹ, H-5ʹʹ), 6.95 (dd, J=7.9, 2.0 Hz, 2H, H-3, H-5), 5.55 (s, 1H, 
CONH), 5.5 (s, 2H, NH2), 3.52 (q, J=7.1 Hz, 1H, H-2ʹ), 2.50 (d J=6.8 Hz, 2H, H-
7ʹʹ), 1.89 (m, 1H, H-8ʹʹ), 1.28 (d, 3H, H-3ʹ), 0.88 (d, J=6.6 Hz, 6H, H-9ʹʹ, H-10ʹʹ); 13C-
NMR (δ): 173 (C-1ʹ), 153.9 (C-4), 135.4 (C-1), 130.9 (C-4ʹʹ), 128.4 (C-6ʹʹ), 127.1 (C-
5ʹʹ), 123.5 (C-6), 115.2 (C-5), 49.0 (C-2ʹ), 44.86 (C-7ʹʹ), 30.66 (C-8ʹʹ), 20.0 (C-3ʹ), 
24.63 (C-9ʹʹ,C-10ʹʹ); ESI-MS: 361.15 [M+H+]; 360.15 C19H24N2O3S. 
 
(A3) 
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2.3.9. Synthesis of prodrug of ibuprofen and isoniazid, N'-(2-(4-
isobutylphenyl) propanoyl) isonicotinohydrazide (A4) 
This compound was synthesized as per procedure for A20 above by replacing aspirin 
chloride with ibuprofen chloride (180 mg, 0.80 mmol) and sulfanilamide by isoniazid 
(110 mg, 0.80 mmol). The purified product (A4) was then characterized. Yield: 178 
mg (68.15). Product (A4) was obtained and characterized; UV-VIS  λ max 225 nm ; IR 
(KBr) ν cm-1: 3337 (NHC=O), 1723 (C=O), 1595 (NH), 1452 (CH), 836 (Ar); 
1H-NMR CDCl3(δ); 8.75 (dd, J=8.3, 2.0 Hz, 2H, H-4 H-6), 8.2 (s, 2H, CONH), 7.6 
(dd, J=8.3, 2.5 Hz, 2H, H-3, H-7), 7.15 (dd, J=8.1, 2.2 Hz, 2H, H-2ʹʹ, H-6ʹʹ), 7.08 (dd, 
J=8.1, 2.2 Hz, 2H, H-3ʹʹ, H-5ʹʹ), 3.7 (q, J=7.2 Hz, 1H, H-2ʹ), 2.49 (d, J=6.8 Hz, 2H, H-
7ʹʹ), 1.88 (m, 1H, H-8ʹʹ), 1.5 (d, J=6.8 Hz, 3H, H-3ʹ), 0.85 (d, J=6.5 Hz, 6H, H-9ʹʹ, H-
10ʹʹ); 13C-NMR (δ): 168.8 (C-1), 148.9 (C-4), 143.5 (C-2), 142.9 (C-1ʹʹ), 130.9 (C-4ʹʹ), 
128.4 (C-2ʹʹ), 127.1 (C-5ʹʹ), 122.1 (C-3), 53.4 (C-2ʹ), 44.8 (C-7ʹʹ), 30.6 (C-8ʹʹ), 24.9 
(C-3ʹ), 24.6 (C-9ʹʹ, C-10ʹ); ESI-MS: 326.1863 [M+H+], 325.1851; C19H23N3O2. 
 
(A4) 
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2.3.10. Synthesis of prodrug of ibuprofen and sulfamethoxazole, 2-(4-
isobutylphenyl)-N-(4-(N-(5-methylisoxazol-3-yl) sulfamoyl) phenyl) 
propanamide (A5) 
This compound was synthesized as per procedure for A20 above by replacing 
sulfanilamide with sulfamethoxazole (202.4 mg, 0.80 mmol) and aspirin chloride by 
ibuprofen chloride (180 mg, 0.80 mmol). The purified product (A5) was then 
characterized. Yield: 251.1 mg 70.8%);  λ max = 260 nm; IR (KBr) ν cm-1 3219 
(NHC=O), 2953 (=CH), 1695 (C=O), 1595 (C=C Ar), 1325 (CN), 1161 (CO); 
1H-NMR CDCl3(δ); 9.6 (s, 1H, SNH), 7.9 (dd, J=7.8, 2.2 Hz, 2H, H-3ʹ), 7.45 (dd, 
J=7.8, 2.1 Hz, 2H, H-2ʹ, H-6ʹ), 7.14 (dd, J=7.9, 2.0 Hz, 2H, H-3ʹʹʹ, H-5ʹʹʹ), 7.09 (dd, 
J=7.9, 1.9 Hz, 2H, H-2ʹʹʹ, H-6ʹʹʹ), 6.0 (s, 1H, CONH), 5.9 (s, 1H, H-4), 3.5 (q, J=7.1 
Hz, 1H, H-2ʹʹ), 2.3 (d, J=6.9 Hz, 2H, H-7ʹʹʹ), 1.9 (s, 3H, H-6), 1.7 (m, 1H, H-8ʹʹʹ), 1.3 
(d, J=7.0 Hz, 3H, H-3ʹʹ), 0.89 (d, J=6.5 Hz, 6H, H-9ʹʹʹ, H-10ʹʹʹ); 13C-NMR (δ): 180.2 
(C-2), 174.4 (C-5), 169.4 (C-1ʹʹ), 142.7 (C-1ʹ), 141.1 (C-4ʹ), 140.8 (C-1ʹʹʹ), 129.3 (C-
4ʹʹʹ), 127.9 (C-3ʹʹʹ), 127.8 (C-3ʹ), 127.3 (C-6ʹʹʹ), 114.2 (C-6ʹ), 96.2 (C-4), 47.5 (C-2ʹʹ), 
45.4 (C-7ʹʹʹ), 30.5 (C-8ʹʹʹ), 22.7 (C-9ʹʹʹ, C-10ʹʹʹ), 19.1 (C-3ʹʹ), 13 (C-6); ESI-MS: 
442.17 [M+H+], 441.17; C23H27N3O4S. 
 
(A5) 
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2.3.11. Synthesis of ibuprofen and sulfamerazine, 2-(4-isobutylphenyl)-N-(4-
(N-(4-methylpyrimidin-2-yl) sulfamoyl) phenyl) propanamide” (A10) 
This compound was synthesized as per procedure for A20 above by replacing 
sulfanilamide with sulfamerazine (132 mg, 0.50 mmol) and aspirin chloride by 
ibuprofen chloride (180 mg, 0.80 mmol). The purified product (A10) was then 
characterized. Yield: 207 mg ( 63%) ;  λ max =235 nm; IR (KBr) ν cm-1: 3205 
(NHCO), 2877(CH), 1697 (C=O), 1593 (C=N), 1541 (NH), 1352 (CH), 
1180 (S=O), 866 (Ar); 1H-NMR CDCl3(δ); 8.2(s, 1H, CONH), 8.14 (d, J=8.1 Hz, 
1H, H-6), 7.25 (s, 1H, SNH), 7.51 (dd, J=8.2, 2.5 Hz, 2H, H-2ʹ, H-6ʹ), 7.32 (dd, 
J=8.2, 2.2 Hz, 2H, H-3ʹ, H-5ʹ), 7.19 (dd, J=8.1, 2.0 Hz, 2H, H-2ʹʹʹ, H-6ʹʹʹ), 7.09 (dd, 
J=8.1, 2.2 Hz,2H, H-3ʹʹʹ, H-5ʹʹʹ), 6.55 (d, J=8.1 Hz, 1H, H-5), 3.81 (q, J=7.2 Hz, 1H, 
H-2ʹʹ), 2.55 (s,3H, H-7), 2.353 (d, J=6.8 Hz, 2H, H-7ʹʹʹ), 1.91 (m, 1H, H-8ʹʹʹ), 1.5 (d, 
J=6.8 Hz, 3H, h-3ʹʹ), 0.89 (d, J=6.5 Hz, 6H, H-9ʹʹʹ, H-10ʹʹʹ); 13C-NMR (δ): 172.9 (C-
1ʹʹ), 156.8 (C-4), 156.5 (C-6), 168.93 (C-2), 151.58 (C-4ʹ), 142.8 (C-1ʹ), 135.7 (C-1ʹʹʹ), 
130.4 (C-4ʹʹʹ), 128.9 (C-3ʹ), 128.2 (C-3ʹʹʹ), 124.0 (C-2ʹʹʹ), 115.3 (C-5), 113.7 (C-2ʹ), 
47.77(C-2ʹʹ), 47.7 (C-7ʹʹʹ), 31.2 (C-8ʹʹʹ), 24.07 (C-9ʹʹʹ, C-10ʹʹʹ), 24.0 (C-7), 19.0 (C-3ʹʹ); 
ESI-MS: 453.1955[M+H+], 452.1961; C24H28N4O3S. 
CH3
 
(A10) 
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2.3.12. Synthesis of prodrug of ibuprofen and metronidazole 2-(2-methyl-5-
nitro-1H-imidazol-1-yl) ethyl 2-(4-isobutylphenyl) propanoate (A11) 
This compound was synthesized as per procedure for A4 above by replacing isoniazid 
with metronidazole (115 mg, 0.67 mmol). The purified product (A11) was then 
characterized. Yield: 194 mg (67%) ; IR (KBr) ν cm-1: 2862 (CH3), 1734 (C=O 
ester), 1641(C=N), 1535 (NO2), 1465 (CH2), 1269 (COC), 1074(CO), 821 
(Ar); 1H-NMR CDCl3(δ); 7.98 (s, 1H, H-4), 7.15 (dd, J=8.1, 2.2 Hz, 2H, H-3ʹʹʹ,H-6ʹʹʹ), 
7.08 (dd, J=8.1, 2.0 Hz, 2H, H-3ʹʹʹ, H-5ʹʹʹ), 4.32 (t, J=5.9 Hz, 2H, H-2ʹ), 4.01 (t, J=5.9 
Hz, 2H, H-1ʹ), 3.68 (q, J=7.2 Hz, 1H, H-2ʹʹ), 2.32 (d, J=6.8, 2H, H-7ʹʹʹ), 2.46 (s, 3H, 
H-6), 1.75 (m, 1H, H-8ʹʹʹ), 1.25 (d, J=6.8 Hz, 3H, H-3ʹʹ), 0.88 (d, J=6.5 Hz, 6H, H-9ʹʹʹ, 
H-10ʹʹʹ); 13C-NMR (δ): 174.5 (C-1ʹʹ), 152.8 (C-2), 140.8 (C-5), 138.1 (C-4), 135.7 (C-
1ʹʹʹ), 130.4 (C-4ʹʹʹ), 128.2 (C-3ʹʹʹ), 124.0 (C-2ʹʹʹ), 63.4 (C-2ʹ), 45.49 (C-2ʹʹ), 45.49 (C-
7ʹʹʹ), 19.17 (C-1ʹ), 30.43 (C-8ʹʹʹ), 24.0 (C-9ʹʹʹ, C-10ʹʹʹ), 15.0 (C-3ʹʹ), 14.49 (C-6); ESI-
MS: 360.1918[M+H+], 359.1927; C19H25N3O4. 
 
(A11) 
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2.3.13. Synthesis of prodrug of Ibuprofen and 7-ADCA, 7-(2-(4-isobutyl 
phenyl)propanamido)-3-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0]oct-2-
ene-2-carboxylic acid (A12). 
This compound was synthesized as per procedure for A4 above by replacing isoniazid 
with 7-ADCA (150 mg, 0.70 mmol). The purified product (A12) was then 
characterized. Yield: 213.4 mg (66%) ; λ max  275 nm; IR (KBr) ν cm-1: 3174 
(NHCO), 2941 (CH3), 1707 (COOH), 1568 (NH), 1463 (CH2), 1035 (CN), 
844 (Ar); 1H-NMR CDCl3(δ); 8.2 (s, 1H, CONH), 7.15 (dd, J=8.1, 2.0,2H, H-2ʹʹ), 
7.08 (dd, J=8.1, 2.2, 2H, H-3ʹʹ, H-5ʹʹ), 5.6 (m, 1H, H-7), 5.2 (d, J=5.1 Hz, 1H, H-6), 
3.82 (q, J=7.2, 1H, H-2ʹ), 2.88 (s, 2H, H-4), 2.49 (d, J=6.8 Hz, 2H, H-7ʹʹ), 1.8 (s, 3H, 
H-9), 1.7 (m, 1H, H-8ʹʹ), 1.35 (d, J=6.8Hz, 3H, H-3ʹ), 0.8 (d, J=6.5 Hz, 6H, H-9ʹʹ, H-
10ʹʹ); 13C-NMR (δ): 179.0 (C-10), 174.5 (C-8), 171.2 (C-1ʹ), 142.9 (C-1ʹʹ), 130.9 (C-
4ʹʹ), 128.9 (C-2), 128.4 (C-6ʹʹ), 127.1 (C-3ʹʹ), 125.1 (C-3), 52.58 (C-7), 46.41 (C-6), 
46.11 (C-2ʹ), 45.8 (C-7ʹʹ), 39.49 (C-4), 30.16 (C-8ʹʹ), 22.26 (C-9ʹʹ, C-10ʹʹ), 18.88 (C-
3ʹ), 8.43 (C-9); ESI-MS: 425.1511[M+Na+], 402.1519; C21H26N2O4S. 
 
(A12) 
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2.3.14. Synthesis of prodrug of ibuprofen and 7-AVCA, 7-(2-(4-isobutyl 
phenyl) propanamido-8-oxo-3-vinyl-5-thia-1-azabicyclo [4.2.0] oct-2-
ene-2-carboxylic acid (A18) 
This compound was synthesized as per procedure for A4 above by replacing isoniazid 
with 7-AVCA (158 mg, 0.70 mmol). The purified product (A18) was then 
characterized. Yield: 219 mg (65.8%) ; UV-Vis. λ max 225 nm ; IR (KBr) ν cm-1: 
3450(OH carboxylic group), 3270 (NHCO), 1779 (C=O β-lactam), 1668 (C=O), 
1608 (C=C), 1581 (N-H), 1379 (COOH), 796 (Ar1H-NMR CDCl3(δ); 8.18 (s, 
1H, CONH), 6.45 (t, J=10.0, 1H, H-10), 7.14 (dd, J=7.9, 2.0 Hz, 2H, H-3ʹʹ, H-5ʹʹ), 
7.09 (dd, J=7.2, 1.9 Hz, 2H, H-2ʹʹ), 5.5 (t, J=5.0 Hz, 1H, H-7), 4.9 (d, J=11.5, 2H, H-
11), 4.79 (d, J=6.0 Hz, 1H, H-6), 3.4 (q, J=7.1 Hz, 1H, H-2ʹ), 2.9 (s, 2H, H-4), 2.28 (d, 
J=6.9 Hz, 2H, H-7ʹʹ), 1.7  (m, 1H, H-8ʹʹ), 1.3 (d, J=7.0 Hz, 3H, H-3ʹ), 0.89 (d, J=6.6 
Hz, 6H, H-9ʹʹ, H-10ʹʹ); 13C-NMR (δ): 171.8 (C-1ʹ), 166.5 (C-8), 162 (C-9), 140.82 
(C-1ʹʹ), 140 (C-9, C-10), 139 (C-3), 128.81 (C-2ʹʹ), 127.37 (C-4ʹʹ), 106.4 (C-2), 75.9 
(C-6), 53.4 (C-2ʹ), 45.11 (C-7), 44.93 (C-7ʹʹ), 30.07(C-8ʹʹ), 30.12 (C-3ʹ), 30.07 (C-4), 
22.3 (C-9ʹʹ, C-10ʹʹ);  ESI-MS: 415.1686 [M+H+], 414.1688; C22H26N2O4S. 
      (A18) 
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2.3.15. Synthesis of flurbiprofen chloride, 2-(2-fluoro-[1, 1ʹ-biphenyl]-4-yl) 
propanoyl chloride [113] 
Solution of flurbiprofen (1.1500 g, 4.7 mmol) was prepared in dry toluene (25 mL). 
To this dry DMF (0.03 mL) was added as catalyst. This was followed by drop wise 
addition of oxalyl chloride (3 mL) as the chlorinating agent; during the addition 
temperature was maintained at 0-5 ºC. Reaction mixture was stirred for overnight. 
The solvent was evaporated on a rotary evaporator. Pure flurbiprofen acid chloride 
was obtained. 1H-NMR: 7.72, (dd, J=7.8, 2.2 Hz, H-6ʹ), 7.55- 7.41 (m, 5H, H-2ʹʹ, H-
3ʹʹ, H-4ʹʹ, H-5ʹʹ, H-6ʹʹ), 7.12 (dd, J=7.8, 2.4 Hz, H-5ʹ), 6.89 (d, J=2.30 Hz, H-3ʹ), 3.81 
(q, J=6.9 Hz, H-2), 1.54 (d, J=6.8 Hz, H-3); 13C-NMR: 173.6 (C-1), 159.2 (C-2ʹ), 
136.8 (C-4ʹ), 136.5 (C-1ʹʹ), 130.0 (C-6ʹ), 129.2 (C-5ʹʹ), 127.9 (C-6ʹʹ), 127.6 (C-4ʹʹ), 
125.7 (C-5ʹ), 117.1 (C-3ʹ), 55.7 (C-2), 16.4 (C-3). 
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2.3.16. Synthesis of prodrug of flurbiprofen and sulfanilamide, N-((4-
aminophenyl) sulfonyl)-2-(2-fluoro-[1, 1’-biphenyl]-4-yl) propanamide 
(A6) 
This compound was synthesized as per procedure for A20 above by replacing aspirin 
chloride by flurbiprofen chloride (113 mg, 0.43 mmol). Quantity of sulfanilamide 
taken for the reaction was (69 mg, 0.40 mmol). The purified product (A6) was then 
characterized. Yield: 109 mg (63.5%) ;  λ max = 270 nm; IR (KBr) ν cm-3070 (=CH), 
2864 (CH), 1693 (C=O amide), 1597 (NH), 1323 (CF), 1151 (S=O), 842 (Ar); 
1H-NMR CDCl3(δ); 7.81 (d, J=8.1 Hz, 1H, H-6ʹʹ), 7.52 (m, 2H, H-2ʹʹʹ), 7.51 (m, 2H, 
H-3ʹʹʹ, H-5ʹʹʹ), 7.50 (d, J=2.10Hz, 1H, H-3ʹʹ), 7.45 (dd, J=8.1, 2.2 Hz, 1H,1H, H-
5ʹʹ),7.41 (m, 1H, H-4ʹʹʹ), 7.28 (dd, J=8.2, 2.1 Hz, 2H, H-2, H-6), 6.65  (dd, J=8.2, 1.9 
Hz, 2H, H-3, H-5), 5.55  (s, 1H, CONH), 4.9 (s, 1H, NH2), 3.65 (q, J=7.1 Hz, 1H, H-
2ʹ), 1.35 (d, J=7.0 Hz, 3H, H-3ʹ); 13C-NMR (δ): 172.8 (C-1ʹʹ), 154.2(C-2ʹʹ), 151.6 (C-
4), 150.4 (C-4ʹʹ), 142.6(C-1), 138.5 (C-1ʹʹʹ), 129.2 (C-3ʹʹʹ), 128.5 (C-1ʹʹ), 127.9 (C-
2ʹʹʹ), 127.1 (C-6ʹʹ), 126.5 (C-4ʹʹʹ), 125.0 (C-5ʹʹ), 124.9 C-2), 115.6 (C-3ʹʹ), 115.5 (C-3, 
C-5), 46.0 (C-2ʹ), 17.6 (C-3ʹ); ESI-MS: 421.0993 [M+Na+], 398.0980; C21H19FN2O3S. 
 
(A6) 
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2.3.17. Synthesis of prodrug of flurbiprofen and sulfamerazine, 2-(2-fluoro-[1, 
1'-biphenyl]-4-yl)-N-(4-(N-(4-methylpyrimidin-2-yl) sulfamoyl) phenyl) 
propanamide (A7) 
This compound was synthesized as per procedure for A20 above by replacing aspirin 
chloride by flurbiprofen chloride (139 mg, 0.50 mmol) and sulfanilamide by 
sulfamerazine (132 mg, 0.50 mmol). The purified product (A7) was then 
characterized. Yield: 181 mg (69.6%) ; λ max 285 nm;  IR (KBr) ν cm: 3251(amide), 
1658 (C=O), 1583 (NH), 1504 (CH), 1348 (CN), 1249 (CF), 1161 (S=O), 891 
(Ar); 1H-NMR CDCl3(δ); 9.2 (s, 1H, CONH), 8.3 (d, J=8.1 Hz, 1H, H-6),6.95(s, 
1H), 7.52-7.48 (m, 5H, H-2ʹʹʹʹ, H-3ʹʹʹʹ, H-4ʹʹʹʹ, H-5ʹʹʹʹ, H-6ʹʹʹʹ), 7.42 (dd, J=7.8, 2.2 Hz, 
1H, H-6ʹʹʹ), 7.24 (dd, J=8.2, 2.5 Hz, 2H, H-6ʹ), 7.20 (d, J=2.20 Hz, 1H, H-3ʹʹʹ), 7.19 
(dd, J=8.2, 2.2 Hz, 2H, H-3ʹ, H-5ʹ), 7.15 (dd, J=7.8, 2.2 Hz, 1H, H-5ʹʹʹ), 6.6 (d, 
J=8.1Hz, 1H, H-5), 3.7 (q, J=6.9 Hz, 1H, H-2ʹʹ), 2.4 (s, 3H, H-7), 1.5 (d, J=6.8 Hz, 
3H, H-3ʹʹ)  ; 13C-NMR (δ): 172.2 (C-1), 169 (C-2) 160(C-4), 159 (C-6), 157.1(C-2ʹʹʹ), 
159 (C-6), 169.9 (C-2), 136.8 (C-4ʹʹʹ), 135.3 (C-4ʹ), 135.1 (C-1ʹʹʹʹ), 131.2 (C-1ʹ), 129.2 
(C-3ʹʹʹʹ), 128.8 (C-1ʹʹʹ), 127.9 (C-2ʹʹʹʹ, C-6ʹʹʹʹ), 127.8 (C-6ʹʹʹ), 127.6 (C-4ʹʹʹʹ), 123.5 (C-
2ʹ), 123.4 (C-5ʹʹʹ), 117.1 (C-3ʹʹʹ), 115.4 (C-3ʹ), 115.2 (C-5), 47.5 (C-2ʹʹ), 24.0 (C-7), 
18.5 (C-3ʹʹ); ESI-MS: 491.2190 [M+H+], 490.2183; C26H23FN4O3S. 
 
(A7) 
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2.3.18. Synthesis of prodrug of flurbiprofen and sulfamethazine, N-(4 (N-(4, 6-
dimethylpyrimidin-2-yl) sulfamoyl)phenyl)-2-(2-fluoro-[1,1'-biphenyl]-
4-yl) propanamide (A8) 
This compound was synthesized as per procedure for A20 above by replacing aspirin 
chloride by flurbiprofen chloride (139 mg, 0.50 mmol) and sulfanilamide by 
sulfamethazine (139 mg, 0.50 mmol). The purified product (A8) was then 
characterized. Yield: 189 mg ( 70.7%) ; λ max 295 nm;  IR (KBr) ν cm: 3334 (amide), 
1680 (C=O), 1584 (NH), 1414 (CF), 1153 (S=O), 831 (Ar); 1H-NMR 
CDCl3(δ); 8.2 (s, 1H, SNH), 7.98 (s, 1H, CONH), 7.55 (s, 1H, H-5), 7.52 (m, 2H, 
H-2ʹʹʹʹ), 7.51 (m, 2H, H-3ʹʹʹʹ), 7.48 (dd, J=8.2, 2.5 Hz, 1H, H-6ʹʹʹ) 7.41 (m, 1H, H-4ʹʹʹʹ), 
7.25 (d, J=8.2, 2.5Hz, 2H, H-2ʹ, H-6ʹ), 7.20 (d, J=2.20 Hz, 3H, H-3ʹ, H-5ʹ, H-3ʹʹʹ), 7.15 
(dd, J=7.8, 2.4 Hz, 1H, H-5ʹʹʹ), 6.7 (s,1H), 3.88 (q, J=6.9 Hz, 1H, H-2ʹʹ), 2.38, (s, 6H, 
H-7, H-8), 1.25 (d, J=6.8 Hz, 3H, H-3ʹʹ); 13C-NMR (δ): 172.4 (C-1ʹʹ), 169.1 (C-6), 
150.9 (C-2), 136.8 (C-4ʹʹʹ), 135.3 (C-4ʹ), 135.1 (C-1ʹʹʹʹ), 131.6 (C-1ʹ), 129.2 (C-5ʹʹʹʹ), 
128.8 (C-1ʹʹʹ), 127.9 (C-6ʹʹʹʹ), 127.8 (C-6ʹʹʹ), 127.6 (C-4ʹʹʹʹ), 123.8 (C-2ʹ), 123.5 (C-6ʹ), 
123.4 (C-5ʹʹʹ), 117.1 (C-3ʹʹʹ), 115.4 (C-5ʹ), 107.5 (C-5), 47.5 (C-2ʹʹ), 24.2 (C-7, C-8), 
18.5 (C-3ʹʹ); ESI-MS: 505.1367 [M+H], 504.1350; C27H25FN4O3S. 
 
(A8) 
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2.3.19. Synthesis of flubiprofen and isoniazid, N'-(2-(2-fluoro-[1, 1’-biphenyl]-
4-yl) propanoyl) isonicotinohydrazide (A9) 
This compound was synthesized as per procedure for A4 above by replacing 
ibuprofen chloride with flurbiprofen chloride (210mg, 0.80 mmol). The purified 
product (A9) was then characterized. Yield:211 mg (72%) ; λ max 270 nm; IR (KBr) 
ν cm-1: 3468 (amide), 1595 (C=O), 1323 (CN), 1143 (CF), 836 (Ar); 1H-1H-
NMR CDCl3(δ);  8.8  (dd, J=7.9, 2.1 Hz, 2H, H-2, H-6), 8.2 (br s, 2H, CONH), 7.52 
(m, 2H, H-2ʹʹʹ, H-6ʹʹʹ), 7.51 (m, 2H, H-3ʹʹʹ, H-5ʹʹʹ), 7.48 (dd, J=7.8, 2.2 Hz, 1H, H-6ʹʹ), 
7.41 (m, 1H, H-4ʹʹʹ), 7.20 (d, J=2.20 Hz, 1H, H-3ʹʹ), 7.15 (dd, J=7.8, 2.4 Hz, 1H, H-
5ʹʹ), 3.8 (q, J=6.9 Hz, 1H, H-2ʹ), 1.55 (d, J=6.8 Hz, 3H, H-3ʹ); 13C-NMR (δ): 172.2 (C-
1ʹ), 171.2 (C-7), 169.0 (C-2ʹʹ), 150.1 (C-2), 143.1 (C-4), 136.8 (C-4ʹʹ), 135.1 (C-1ʹʹʹ), 
129.2 (C-5ʹʹʹ), 128.8 (C-1ʹʹ), 127.8 (C-6ʹʹ), 127.6 (C-4ʹʹʹ), 127.2 (C-2ʹʹʹ), 123.4 (C-5ʹʹ), 
123.1 (C-5), 117.1 (C-3ʹʹ), 47.5 (C-2ʹ), 18.5 (C-3ʹ); ESI-MS: 364.1456 [M+H+], 
365.1446; C21H18FN3O2. 
 
(A9) 
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2.3.20. Synthesis of prodrug of flurbiprofen and metronidazole, 2-(2-methyl-5-
nitro-1H-imidazol-1-yl) ethyl 2-(2-fluoro-[1, 1'-biphenyl]-4-yl) 
propanoate (A13) 
This compound was synthesized as per procedure for A4 above by replacing isoniazid 
with metronidazole (115 mg, 0.70 mmol) and ibuprofen chloride by flurbiprofen 
chloride (183 mg, 0.70 mmol). The purified product (A13) was then characterized. 
Yield: 193 mg (69%) ;λ max 310 nm; IR (KBr) ν cm-1: 1737 (C=O ester), 1641 
(C=C), 1529 (NO2), 1463 (CH2), 1365 (CH3), 1261 (C(O)C), 1178 (CF), 
1072 (CN), 869 (Ar); 1H-NMR CDCl3(δ); 8.2 (br,s, 1H, H-1ʹʹ ), 8.0 (s, 1H, H-4), 
7.55 (m, 1H, H-6ʹʹʹʹ), 7.54 (m, 1H, H-2ʹʹʹʹ),  7.53 (m, 1H, H-3ʹʹʹʹ), 7.48 (dd, J=7.8, 2.2 
Hz, 1H, H-6ʹʹʹ), 7.41 (m, 1H, H-4ʹʹʹʹ), 7.20 (d, J=2.2 Hz, 1H, H-3ʹʹʹ), 7.15 (dd, J=7.8, 
2.4 Hz, 1H, H-5ʹʹʹ), 4.45 (t, J=5.5 Hz, 2H, H-2ʹ), 4.15 (t, 5.5 Hz, 2H, H-1ʹ), 3.88 (q, 
J=6.9 Hz, 1H, H-2ʹʹ), 2.56 (s, 3H, H-6), 1.25 (d, J=6.8 Hz, 3H, H-3ʹʹ); 13C-NMR (δ): 
172.6 (C-1ʹʹ), 169.5 (C-2), 169.0 (C-2ʹʹʹ), 141.5 (C-5), 136.8 (C-4), 129.2 (C-3ʹʹʹʹ, C-
5ʹʹʹʹ), 128.8 (C-1ʹʹʹ), 127.8 (C-6ʹʹʹ), 127 (C-2ʹʹʹʹ, C-6ʹʹʹʹ), 123.4 (C-5ʹʹʹ), 122.2 (C-4ʹʹʹʹ), 
117.1 (C-3ʹʹʹ), 63.9 (C-2ʹ), 47.5 (C-2ʹʹ), 45.6 (C-1ʹ), 18.5 (C-3ʹʹ), 15.5 (C-6);  ESI-MS: 
398.1511  [M+H+], 397.1506; C21H20FN3O4. 
 
(A13) 
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2.3.21. Synthesis of prodrug of flurbiprofen and sulfamethoxazole, 2-(2-fluoro-
[1, 1’-biphenyl]-4-yl)-N-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl) 
phenyl) propanamide (A14) 
This compound was synthesized as per procedure for A20 above by replacing aspirin 
chloride by flurbiprofen chloride (139 mg, 0.50 mmol) and sulfanilamide by 
sulfamethoxazole (202.4 mg, 0.80 mmol). The purified product (A14) was then 
characterized. Yield 168 mg (66%); λ max  245 nm; IR (KBr) ν cm-1: 3265 (amide), 
1681 (C=O amide), 1600 (NH), 1388 (CF), 1259 (CON), 1165 (S=O), 920 
(CO), 819 (Ar); 1H-NMR CDCl3(δ); 8.2 (br.s. 1H, CONH), 7.55 (m, 1H, H-6ʹʹʹʹ), 
7.54 (m, 1H, H-2ʹʹʹʹ), 7.53 (m, 2H, H-5ʹʹʹʹ), 7.48 (dd, J=7.8, 2.2 Hz, 1H, H-6ʹʹʹ),7.45 
(dd, J=7.8, 2.2 Hz, 2H, H-3ʹ, H-5ʹ), 7.44 (dd, J=7.8, 2.1 Hz, 2H, H-2ʹ), 7.41 (m, 1H, 
H-4ʹʹʹʹ), 7.20 (d, J=2.2 Hz, 1H, H-3ʹʹʹ), 7.15 (dd, J=7.8, 2.4 Hz, 1H, H-5ʹʹʹ), 6.9 (s, 1H, 
SNH), 5.55 (s, 1H, H-4), 3.88 (q, J=6.9 Hz, 1H, H-2ʹʹ), 2.25 (s, 3H, H-6), 1.25 (d, 
J=6.8Hz, 3H, H-3ʹʹ); 13C-NMR (δ): 177.1 (C-3), 172.4 (C-1ʹʹ), 170.2 (C-5), 169.0 (C-
2ʹʹʹ), 142.6 (C-1ʹ), 141.5 (C-4ʹ), 136.8 (C-1ʹʹʹʹ), 129.2 (C-3ʹʹʹʹ, C-5ʹʹʹʹ), 128.8 (C-1ʹʹʹ), 
127.8 (C-6ʹʹʹ), 127 (C-2ʹʹʹʹ, C-6ʹʹʹʹ), 126.8 (C-3ʹ), 123.4 (C-5ʹʹʹ), 122.2 (C-4ʹʹʹʹ), 117.1 
(C-3ʹʹʹ), 112.5 (C-6ʹ), 89.1 (C-4), 47.5 (C-2ʹʹ), 18.5 (C-3ʹʹ), 13.1 (C-6);  ESI-MS: 
502.1207 [M+Na+], 479.1198; C25H22FN3O4S. 
(A14) 
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2.3.22. Synthesis of prodrug of flurbiprofen and 7-ADCA, 7-(2-(2-fluoro-[1, 1’-
biphenyl]-4-yl) propanamido) -3-methyl-8-oxo-5-thia-1-azabicyclo 
[4.2.0] oct-2-ene-2-carboxylic acid (A16). 
This compound was synthesized as per procedure for A4 above by replacing isoniazid 
with 7-ADCA (150 mg, 0.70 mmol) and ibuprofen chloride by flurbiprofen chloride 
(183 mg, 0.70 mmol). The purified product (A16) was then characterized. Yield: 226 
mg(70%) ; λ max UV-Vis. λ max 238 nm; IR (KBr) ν cm-1: 3468 (OH carboxylic 
group), 1775 (C=O β-lactam), 1681(C=O amide) 1595 (NH), 1085 (CF), 836 
(Ar); 1H-NMR CDCl3(δ);  8.22 (s,1H, COOH), 8.1 (m, 1H, CONH), 7.52 (m, 2H, 
H-2ʹʹʹ, H-6ʹʹʹ), 7.51 (m, 2H, H-3ʹʹʹ, H-5ʹʹʹ), 7.45 (dd, J=7.8, 2.2 Hz, 1H, H-6ʹʹ), 7.41 
(m,1H, H-4ʹʹʹ), 7.25 (d, J=2.20 Hz, 1H, H-3ʹʹ), 7.10 (dd, J=7.8, 2.4 Hz, 1H, H-5ʹʹ), 6.6 
(m, 1H, H-7), 5.1 (d, J=5.1 Hz, 1H, H-6), 3.81(q, J=6.9 Hz, 1H, H-2ʹ), 3.7 (s, 2H, H-
4), 2.45 (s, 3H, H-10), 1.5 (d, J=6.8 Hz, 3H, H-3ʹ); 13C-NMR (δ): 179.8 (C-9) , 174.5 
(C-8), 172.2 (C-1ʹ), 169.0 (C-2ʹʹ), 152.0 (C-4ʹʹ), 136.8 (C-1ʹʹʹ), 129.2 (C-3ʹʹʹ, C-5ʹʹʹ), 
128.9 (C-2), 128.8 (C-1ʹʹ), 127.8 (C-6ʹʹ), 127 (C-2ʹʹʹ, C-6ʹʹʹ), 125.1 (C-3), 123.5 (C-
4ʹʹʹ), 123.4 (C-5ʹʹ), 117.1 (C-3ʹʹ), 65.5 (C-7), 52.5 (C-6), 47.5 (C-2ʹ), 30.7 (C-4), 18.5 
(C-3ʹ), 14.2 (C-10);  ESI-MS: 441.1279 [M+H+], 440.1276; C23H21FN2O4S. 
 
(A16) 
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2.3.23. Synthesis of prodrug of flurbiprofen and 7-AVCA, 7-(2-(2-
fluorobiphenyl-4-yl) propanamido)-3-methyl-8-oxo-5-thia-1-azabicyclo 
[4.2.0] oct-2-ene-2-carboxylic acid (A17) 
This compound was synthesized as per procedure for A4 above by replacing isoniazid 
with 7-AVCA (158 mg, 0.70 mmol) and ibuprofen chloride by flurbiprofen chloride 
(183 mg, 0.70 mmol). The purified product (A17) was then characterized. Yield 213 
mg (67.6%) ; λ max  250 nm; IR (KBr) ν cm-1: 3400(OH carboxylic group), 3180 
(amide), 1779 (C=O β-lactam), 1670 (C=O), 1595 (NH), 1373 (COOH), 1031 
(CF), 770 (Ar); 1H-NMR CDCl3(δ); 8.15 (s, 1H, COOH), 7.69 (s, 1H, CONH), 
7.55 (m, 1H, H-6ʹʹʹ), 7.54 (m, 1H, H-2ʹʹʹ), 7.53 (m, 2H, H-3ʹʹʹ), 7.48 (dd, J=7.8, 2.2 Hz, 
1H, H-6ʹʹ), 7.43 (m, 1H, H-10), 7.41 (m, 1H, H-4ʹʹʹ), 7.20 (d, J=2.20 Hz, 1H, H-3ʹʹ), 
7.15 (dd, J=7.8, 2.4 Hz, 1H, H-5ʹʹ), 6.61 (d, J=11.5 Hz, 2H, H-11), 5.05 (t, J=5.0 Hz, 
1H, H-7), 4.85 (d, J=6.0 Hz, 1H, H-6), 3.89 (q, J=7.1Hz, 1H, H-2ʹ), 3.77 (s, 2H, H-4), 
1.25 (d, J=7.0 Hz, 3H, H-3ʹ); 13C-NMR (δ): 179.98 (C-9), 174.5 (C-8), 172.0 (C-1ʹ), 
169.0 (C-2ʹʹ), 152.0 (C-4ʹʹ), 135.1 (C-1ʹʹʹ), 129.2 (C-3ʹʹʹ, C-5ʹʹʹ), 128.8 (C-1ʹʹ), 127.8 
(C-6ʹʹ), 127.3 (C-11), 127.1 (C-10), 127 (C-2ʹʹʹ, C-6ʹʹʹ), 123.9 (C-3), 123.5 (C-4ʹʹʹ), 
123.4 (C-5ʹʹ), 117.1 (C-3ʹʹ), 123.69 (C-2), 52.75 (C-6), 53.4 (C-7), 45.42 (C-2ʹ), 
239.29 (C-4), 19.3 (C-3ʹ);  ESI-MS: 451.1686 [M+H+], 452.1688; C24H21FN2O4S. 
 
(A17) 
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2.3.24. Synthesis of prodrug of ibuprofen and ampicillin sodium, 6-(2-(2-(4-
isobutylphenyl) propanamido)-2-phenylacetamido)-3, 3-dimethyl-7-
oxo-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylate (A1) 
This reaction was planned according to the method given in literature [114] with 
slight modification. The solution of ampicillin (35 mg, 0.1 mmol) was prepared in 
acetonitrile (CH3CN, 15 mL). DCCI (20 mg, 0.1 mmol) and a catalytic amount of 
DMAP (2.5 mg, 0.02 mmol) were added in ampicillin solution. Solution of ibuprofen 
(20.6 mg, 0.1 mmol) in acetonitrile (CH3CN, 15 mL) was prepared and added to first 
solution at 0 oC. The mixture was stirred first at 0 oC for 15 min then at about 25 0C 
for 24 h. The reaction mixture was filtered to remove dicyclohexyl urea (DCU), the 
residues were washed with CH3CN (25 mL), and the combined filtrates were 
evaporated in vacuum. Product was purified using flash column chromatography. 
TLC (pre-coated silica gel GF-254, 0.5 mm thick, Merck; 1:1 ethyl acetate: 
acetonitrile): 30 mg (54.4%) yellowish coloured solid(A1) ; λ max = 300 nm; IR (KBr) 
ν cm-1: 3298 (Carboxylic group), 1649 (C=O), 1598 (CH), 1519 (NHC=O), 
1388 (CH3CHCH3), 1130 (CN); 1H NMR (δ): 8.1 (m, 2H, CONH), 7.39 (dd 
(J=7.9, 2.0 Hz, 2H, H-5ʹʹ), 7.35( dd, J=7.2, 1.9 Hz, 1H, H-4ʹʹ),  7.3 (dd, J=8.2, 2.5 Hz, 
2H, H-2ʹʹʹʹ, H-6ʹʹʹʹ), 7.20 (m, 2H, H-6ʹʹ), 7.09 (dd, j=8.2, 2.2 Hz, 2H, H-3ʹʹʹʹ, H-5ʹʹʹʹ), 
5.55 (d J=4.5 Hz, 1H, H-6), 5.6 (s, 1H, H-2ʹ), 4.8, (d, J=4.5Hz, 1H, H-5), 5 (s,1H),  
4.44 (s, 1H, H-2), 3.8 (q, J=7.1 Hz, 1H, H-2ʹʹʹ), 2.40 (d J=6.6 Hz, 2H, H-7ʹʹʹʹ), 1.89 (m, 
1H, H-8ʹʹʹʹ), 1.2 (s, 6H, H-9, H-10) 1.4 (d, J=6.9 Hz, 3H, H-3ʹʹʹ), 0.9 (d, J=6.6 Hz,6H, 
H-9ʹʹʹʹ, H-10ʹʹʹʹ);  13C NMR (CDCl3): 179.0 (C-8), 178.0 (C-1ʹ), 177.0 (C-1ʹʹʹ), 174.0 
(C-7), 140.5 (C-1ʹʹ), 139.2 (C-1ʹʹʹʹ), 129.3 (C-2ʹʹ), 128.7 (C-3ʹʹ), 127.6 (C-4ʹʹ), 127.3 
(C-2ʹʹʹʹ, C-6ʹʹʹʹ), 127.2 (C-3ʹʹʹʹ, C-5ʹʹʹʹ), 71 (C-2), 69 (C-5), 67 (C-3), 63  (C-6), 57.3 (C-
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2ʹʹʹ), 60 (C-2ʹ), 42.0 (C-7ʹʹʹʹ), 28.64 (C-8ʹʹʹʹ), 26.5 (C-9ʹʹʹʹ, C-10ʹʹʹʹ), 25.36 (C-9, C-10), 
25.32 (C-3ʹʹʹ); ESI-MS: 560.2190 [M+H+], 559.218; C29H34N3NaO5S 
(A1)  
2.3.25. Synthesis of prodrug of flurbiprofen and ampicillin sodium sodium 6-
(2-(2-(2-fluoro-[1, 1’-biphenyl]-4-yl) propanamido)-2-
phenylacetamido)-3, 3ʹ-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0] 
heptane-2-carboxylate (A15) 
This compound was synthesized as per procedure for A1 above by replacing 
ibuprofen with flurbiprofen (24.4 mg, 0.1 mmol).The purified product (A15) was then 
characterized. Yield 35.5 mg (59.5%); λ max 290 nm; IR (KBr) ν cm-1: 3244(amide), 
1774 (C=O β-lactam), 1643 (C=O), 1558 (NH), 1386 (CF), 1215 (CO 
carboxylate), 808 (Ar); 1H-NMR CDCl3(δ); 8.2 (br.s., 1H, CONH), 7.55 (m, 1H, 
H-6ʹʹʹʹ), 7.54 (m, 1H, H-2ʹʹʹʹ), 7.53 (m, 2H, H-3ʹʹʹʹ), 7.48 (dd, J=7.8, 2.2 Hz, 1H, H-
6ʹʹʹ), 7.41 (m, 1HH-4ʹʹʹʹ), 7.39 (dd, J=7.9, 2.0 Hz, 2H, H-3ʹ, H-5ʹ), 7.35 (dd, J=7.2, 1.9 
Hz, 1H, H-4ʹ), 7.20 (m, 2H, H-6ʹ), 7.15 (dd, J=7.8, 2.4 Hz, 1H, H-5ʹʹʹ), 5.55 (d, J=4.5 
Hz, 1H, H-6), 5.19 (s, 1H, H-1ʹʹʹʹʹ), 5.16 (d, J=4.5 Hz, 1H, H-5), 4.44 (s, 1H, H-2), 
3.88 (q, J=6.9 Hz, 1H, H-2ʹʹ), 1.60 (s, 6H, H-8, H-9), 1.25 (d, J=6.8 Hz, 3H, H-3ʹʹ);  
13C-NMR (δ): 175.6 (C-10), 172.2 (C-1ʹʹ), 171.5 (C-2ʹʹʹʹʹ), 171.1 (C-7), 169.0 (C-2ʹʹʹ), 
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140.5 (C-1ʹ), 136.8 (C-1ʹʹʹʹ), 129.3 (C-2ʹ), 129.2 (C-3ʹʹʹʹ, C-5ʹʹʹʹ), 128.8 (C-1ʹʹʹ), 128.7 
(C-3ʹ, C-5ʹ), 127.8 (C-6ʹʹʹ), 127.6 (C-4ʹ), 127 (C-2ʹʹʹʹ, C-6ʹʹʹʹ), 123.4 (C-5ʹʹʹ), 122.2 (C-
4ʹʹʹʹ), 117.1 (C-3ʹʹʹ), 75.9 (C-5), 75.8 (C-2), 59.6 (C-3), 58.4 (C-6), 57.2 (C-1ʹʹʹʹʹ), 47.5 
(C-2ʹʹ), 25.3 (C-8, C-9), 18.5 (C-3ʹʹ);  ESI-MS: 598.1782 [M+H+],  597.1776; 
C31H29FN3NaO5S. 
(A15) 
2.4. List of successful reactions of antibiotics and anti-inflammatory 
drugs 
Benzydamine HCl + cefazolin sodium (A) 
Ibuprofen +  ampicillin sodium  (A1) 
Ibuprofen +  sulfamethazine  (A2) 
Ibuprofen +  sulfanilamide  (A3) 
Ibuprofen +  isoniazid   (A4) 
Ibuprofen +  sulfamethoxazole  (A5) 
Ibuprofen +  sulfamerazine  (A10) 
Ibuprofen + metronidazole  (A11) 
Ibuprofen +  7-ADCA   (A12)          
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Ibuprofen +  7-AVCA   (A18) 
Flurbiprofen + sulfanilamide  (A6) 
Flurbiprofen + sulfamerazine  (A7) 
Flurbiprofen + sulfamethazine  (A8) 
Flurbiprofen + isoniazid   (A9) 
Flurbiprofen + metronidazole  (A13) 
Flurbiprofen + sulfamethoxazole  (A14) 
Flurbiprofen + ampicillin sodium  (A15) 
Flurbiprofen +7-ADCA   (A16)         
Flurbiprofen +7-AVCA   (A17) 
Aspirin + sulfanilamide   (A20) 
Aspirin + sulfamethoxazole  (A24) 
Aspirin + sulfamerazine   (A25) 
2.5. Characterization 
The intermediates and products were characterized by determination of melting points 
and spectroscopic techniques including FT-IR, 1HNMR, 13CNMR, ESI-MS and single 
crystal XRD.  
2.5.1. Melting point  
Melting points were determined in the glass capillaries using Gellenkemp melting 
point apparatus and are reported uncorrected. 
2.5.2. Spectroscopic techniques  
Electronic spectra were recorded in the UV region in methanol using Cecil 7200 
spectrometer. FT-IR spectra were recorded on Thermo Nicolet, M2000 and 460 
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Shimadzu Spectrometer in the reflectance mode. The 1H and 13C-NMR spectra were 
recorded on Bruker AV400 and Bruker DPX 200 spectrometers respectively. The 
chemical shifts were reported in parts per million on the δ scale. The J values were 
reported in Hz. Electron impact mass spectra (ESI-MS) were recorded on Waters LCT 
Premier Open Access System. Chemical shifts in NMR data were reported as: singlet 
as s, doublet as d, triplet as t, quartet as q, multiplet as m, broad as br. 
2.6. Biological Studies 
2.6.1. Antibacterial activities [115, 116] 
Materials  
The organisms used were: Bacillus licheniformis (ATCC 14580), Bacillus subtilis 
(ATCC 6051), Bacillus amyliquefaciens (ATCC 23350), Bacillus thurigenesis (ATCC 
35646), Staphylococcus aureus (ATCC 25923), Escherichia coli (ATCC9637). The 
standard drugs used were: ampicillin, sulfamethazine, sulfamerazine, 
sulfamethoxazole, sulfanilamide, metronidazole, isoniazid, 7-ADCA and 7-AVCA.  
Preparation of growth media  
Nutrient broth: Bacto nutrient broth-Difco 0003 (0.8 g) was dissolved in 100 mL 
distilled water by heating. After adjusting the pH to 7.4, the broth was sterilized in an 
autoclave for 20 min at 121°C. 
Nutrient agar: Bacto Nutrient broth-Difco 0003 (0.8 g) was dissolved in distilled 
water (100 mL) by heating. The pH was adjusted to 7.4. To this Difco 214520 agar 
(1.5 g) was added and the mixture was heated to obtain clear solution and sterilized in 
an autoclave at 121°C for 20 minutes. 
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Preparation of inoculum  
The stock slants were cultured and loop-full of cultures was added to the sterilized 
slants in the test tubes. These cultures were incubated in an incubator at 37°C for 24 
hours. A loop full from these cultures was transferred to the freshly prepared nutrient 
broth (50ml) and was incubated at 37°C for 24 hours in a shaker. These bacterial 
cultures served as inoculum.  
Procedure 
Antibacterial activity was determined by well diffusion method. All bacterial species 
were maintained on the nutrient agar slants. Nutrient agar was melted at 50 0C and 
then was mixed with 5 ml of prepared inoculums (of respective test cultures). These 
were then poured onto sterilized petri dishes. Lids were put on the dishes. These were 
allowed to cool and solidify. 5 mm diameter wells cut in the agar gel; these were 60 
mm apart from each other. 100 μL (prodrug/reference standard) solutions were added 
into each well. The petri dishes were kept in the flat position for one and half hour and 
then these were incubated at 37 oC for 24 hours under aerobic conditions. Inhibition 
(zone) was recorded in mm. Tests were done in triplicate with prodrug and reference 
standard solutions. All the sample solutions were prepared at the concentration of 
100μg/mL of DMSO. 100 μL of these solutions was added into each well; total 
quantity of the drugs added in the wells was equal to 10 μg / well. Equivalent quantity 
of DMSO was used as control. The results were recorded in the results and discussion 
section. 
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Table 3: Concentrations of antibiotics used 
Antibiotics nmoles/well Antibiotics nmoles/well 
Metronidazole 58 7-ADCA 47 
Sulfamethazine 36 7-AVCA 44 
Sulfamerazine 38 Sulfanilamide 58 
Isoniazid 73 Ampicillin 27 
Sulfamethoxazole 39   
 
Table 4: Concentration of prodrugs used (ibuprufen) 
Prodrugs nmoles/well Prodrugs nmoles/well 
A1 18 A10 22 
A2 21 A11 28 
A3 28 A12 25 
A4 31 A18 24 
A5 23   
 
Table 5: Concentration of prodrugs used (flurbiprofen) 
Prodrugs nmoles/well Prodrugs nmoles/well 
A6 25 A14 21 
A7 20 A15 17 
A8 19 A16 23 
A9 28 A17 22 
A13 24   
 
Table 6: Concentration of prodrugs used (aspirin) 
Prodrugs nmoles/well 
A20 30 
A24 23 
A25 22 
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2.6.2. Enzyme inhibition study 
Lipoxygenase activity 
Anti-inflammatory activity can be performed in vitro by different methods including 
Lipoxygenase (LOX) inhibition by the test compound [117,118] which was used in 
the present work. The LOX activity was assayed according to a reported method [119] 
with slight modifications. Briefly, the test compound (20 µL, 0.5 mM) was added to 
100 mM phosfate buffer pH 8.0 (140 µL). To this LOX from soybean (15 µL, 600 
units well-1, Sigma) was added. The contents were vortex-mixed and the absorbance 
at 234 nm was recorded. Then the mixture was incubated at 25°C for 10 min. The 
reaction was initiated by the addition of substrate solution of linoleic acid (25 µL). 
Change in the absorbance was recorded after 6-10 min at 234 nm using Synergy HT 
96-well plate reader (BioTek, USA). Baicalein (20µL, 0.5 mM) was added as a 
positive control in each well.  For determination of IC50 values, solutions of the test 
compound were assayed at 0.5 mM, 0.25 mM, 0.125 mM, 0.0625 mM, 0.0313 mM, 
0.015 mM concentrations.  IC50 values of active compounds were calculated using 
EZ–Fit Enzyme kinetics software (Perrella Scientific Inc. Amherst, USA) using the 
formula” 
 
Where, Acont = total enzyme activity without inhibitor, Ats = activity in the presence 
of test compound. 
Acetylcholinesterase assay 
The Acetylcholinesterase (AChE) inhibition assay was performed according to a 
reported method [120] with few modifications. Briefly, the reaction mixture contained 
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50 mM phosfate buffer pH 7.7 (60 µL), the test compound (10 µL, 0.5 mM) and 
AChE (10 µL, 0.005 units) in each well. The contents were vortex-mixed and 
absorbance at 405 nm was recorded using Synergy HT 96-well plate reader (BioTek, 
USA). The mixture was then incubated for 10 min at 37oC. The reaction was initiated 
by the addition of 0.5 mM acetylthiocholine iodide (10 µL) in each well as substrate. 
Then to each well 0.5 mM 5,5-dithiobis-(2-nitrobenzoic acid (DTNB, 10 µL) was 
added and, after incubation at 37ºC for 30 min, absorbance was recorded at 405 nm. 
Experiments were carried out in triplicate. Eserine (10 µL, 0.5 mM) was used as a 
positive control in each well. The percentage inhibition was calculated by the help of 
following equation.” 
 
Butyrylcholinesterase assay 
This assay was carried out according to the procedure for AChE by replacing the 
enzyme with Butyrylcholinesterase (BChE) and the substrate by butyrylthiocholine 
bromide.  
 α -Chymotrypsin assay 
The α-chymotrypsin inhibition activity is performed according to a reported method 
[121] with few modifications. Briefly, the reaction mixture contained Tris-HCl buffer 
pH 7.6 (60μL), the test compound (10μL, 0.5 mM) and purified α-chymotrypsin 
(15μL, 0.9 units) in each well. The contents were vortex-mixed and absorbance at 410 
nm was recorded using Synergy HT 96-well plate reader (BioTek, USA). The mixture 
was then incubated for 10 min at 37oC. The reaction was initiated by the addition of 
1.3 mM N-succinyl-L-phenyl-alanine-p-nitroanilide, (15 μL). The change in 
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absorbance was recorded after 30 min at 410 nm. Experiments were carried out in 
triplicate. The positive and negative controls were included in the assay. Chymostatin 
(10 µL, 0.5 mM) was used as a standard inhibitor in each well. The percentage 
inhibition was calculated by the help of following equation.” 
 
IC50 values (concentration at which there is 50% enzyme inhibition) of compounds 
were calculated using EZ–Fit Enzyme kinetics software (Perrella Scientific Inc. 
Amherst, USA). 
Free radical scavenging activity 
1, 1-Diphenyl-2-picrylhydrazyl radical (DPPH) was used for the determination of 
antioxidant activity according to a reported method [122] with minor modifications. 
Briefly, the test solution (10 µL, 0.5 mM) was added to methanolic 100 µM DPPH 
solution (90 µL) in 96-well plates. The contents were mixed and incubated at 37 0C 
for 30 min. The absorbance was measured at 517 nm using Synergy HT BioTek USA 
microplate reader. Quercetin (10 µL, 0.5 mM) was used as a standard in each well. 
All the experiments were carried out in triplicate. IC50 values of these drugs were 
calculated. A decrease in absorbance indicates increased radical scavenging activity, 
which was determined by the formula.” 
The percentage inhibition was calculated by the help of following equation. 
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2.6.3. Anti-tuberculosis activity 
Materials 
The organism used was Mycobacterium tuberculosis obtained directly from the 
sputum of the patients. Isoniazid was the standard drug used. 
Preparation of growth media  
Löwenstein–Jensen (LJ) drug-containing media were used for drug susceptibility 
testing (DST) of Mycobacterium tuberculosis according to the proportion method 
[123].In proportion method, relative growth of a definite inoculum can be determined 
on a drug free (control) medium while comparing it with growth on culture medium 
containing its critical concentration of drug used.  
LJ medium is most commonly used for preparing mycobacterial culture and it is 
recommended by World health organisation (WHO). Components used for the 
preparation of this medium were mixed in the following sequence: Anhydrous 
monopotassium dihydrophosulfate (2.4 g), magnesium sulfate (0.24), Magnesium 
citrate (0.6) and L-asparagine (3.6) were dissolved in distilled water (600 mL). 
Glycerol (12mL) was added in to this solution. Eggs were beaten to make a 
homogenate. Egg homogenate (1000mL) and 2% malachite green (20 mL) were 
added in to the above mentioned solution. Then pH was adjusted at about 6.8. This 
medium (7 mL in each slope) was added in a number of slopes and was put in hot air 
oven at 85oC for 45 min and then was left in incubator at 37oC for 2 days. 
As this medium was heated at 85oC, during heating, egg proteins were coagulated and 
were solidified on cooling; that’s why no separate agar was added into the medium for 
preparation of the culture media. 
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Preparation of inoculum 
Sputa of TB patients with smear grading of 2+ were used for preparing pure cultures. 
Sputa were digested and decontaminated using N-acetyl-L-cysteine-NaOH-Na citrate 
standard method [124], and concentrated by centrifugation for 15 min at 3000. 
Sediments were separated and re-suspended in sterile buffer (0.85%) to a volume of 1 
mL. Serial dilutions of the sputum concentrate were prepared. The diluted 
suspensions (0.1mL) were used for inoculation. Inoculum was distributed evenly on 
the culture medium in growth tubes.  
Procedure (Serial dilution for drug sensitivity testing, DST) 
Loop full of colonies were taken from growth tubes and were added to screw capped 
tubes containing 5-7 glass beads with sterilized water (0.3 mL) in each tube. These 
were gently vortex for one minute and were then left for 10 min. Sterilized water (5 
mL) was added into these and again left for 20 min. Supernatant from all tubes was 
taken into other labelled tubes. Turbidity was checked to be equal to 1 McFarland. 4 
tubes were taken and labelled as 10-1, 10-2, 10-3, 10-4. 1 McFarland turbidity (1 mL) 
was taken and added in the tube labelled 10-1. Distilled water (9 mL) was added in to 
it. It was gently mixed, then 1 mL was taken from this mixture and added to tube 
labelled as10-2. Distilled water (9 mL) was added in this and was mixed gently. 10-3 
and 10-4 were prepared similarly. Concentrations labelled as 10-2 and 10-4 were used as 
controls in DST. Isoniazid and the prodrugs (A4 and A9) were used at the 
concentration of 0.2, 0.48 and 0.5 µg mL-1 respectively. These were all 1.5x10-6 M 
solution which is actually critical concentration value for isoniazid. These solutions 
were then added into 10-2 dilution of each isoniazid, A4 and A9. These labelled tubes, 
containing all the test material, were incubated at 36±1 oC. Screw capped bottles were 
used for the purpose to allow a little gas exchange. The inoculated media was 
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examined after 1 week of inoculation to check any contamination. Media was allowed 
to be inoculated for further 5 weeks. Drug susceptibility was observed & interpreted 
after 6 weeks of incubation.  
2.6.4. Toxicity 
Acute toxicity 
All the steps were performed following “OECD (Organisation for economic co-
operation and development) guide lines [125] for the testing of chemicals/drugs in the 
animals”. The animals, albino mice, were randomly selected, were marked to permit 
individual identification, and kept in their cages for 5 days prior to dosing. The 
animals were housed under natural light and dark cycles. The animals were randomly 
divided into three groups as control, positive control and test. Each group consisted of 
four animals. Mice (8-10 weeks; 25-30 g) of either sex obtained from the University 
animal house were used. They were allowed standard laboratory feed and water. 
Animals were acclimatized to this environment. The starting dose was set on 300 mg 
kg-1 body weight as no information was available for the toxicity of the synthesized 
compounds. The volume of the dose (as aqueous suspension) administered was 2 
mL/100 g body weight. The mice were made to fast prior to dosing for 3 hours for 
food but not water. After that the animals were weighed and single dose of the test 
compound was administered using a stomach tube (gavage). After the drug 
administration, food was withheld for 1 h. The animals were observed individually 
after dosing during the first 30 min, carefully for next 4 h, and daily for total 14 days. 
The observations included behaviour, sleep, food and water intake, body weight and 
mortality. 
62 
 
Sub chronic toxicity 
This study was carried out after getting information on acute toxicity. This involved 
90 days repeated doses study to provide information on all possible health risks which 
can arise on repeated exposure of the test compounds over a long period of time. The 
test drugs were orally administered daily to three groups, control, and positive control 
and treated, of mice (20; 10 male, 10 female in each group) housed and fed as 
described for the acute toxicity test for a period of 90 days. The dose was 100 mg kg-1 
body weight in the form of aqueous suspension (2 mL per 100 g body weight) 
administered by gavage. The control group received distilled water only. Observations 
were recorded at pre-determined intervals of time on daily basis. Body weight and 
behavioural changes were recorded after administration of the 7th dose. 
2.7. Computational analysis  
All the structures of the parent drugs and mutual prodrugs were drawn in ChemDraw 
Ultra 12.0, optimized and saved as ‘mol’ files. These files were uploaded on ACD/I-
Lab2. Properties like, logBB, logPS and LD50 were predicted by the software. LogBB 
is the logarithmic ratio between concentration of a drug in brain and blood. Drugs 
having logBB ≥ 0 are permeable and logBB ≤ 0 are considered as nearly non-
permeable. LogPS, permeability surface product, determines the drug transfer across 
the blood-brain barrier (BBB). All these properties were recorded for the parent and 
the synthesized prodrugs. Other drug-like properties, including absorption, 
distribution (ADME), were also computed because they could not be determined 
experimentally due to non-availability of sufficient quantities of the synthesized 
compounds [126].  
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3. Results and Discussion 
Keeping in view necessity of prescribing NSAIDs concomitantly with antibiotics it is 
thought that the two molecules could be covalently coupled to produce a single 
molecule with anti-bacterial and anti-inflammatory activities. Thus some of the anti-
bacterial, including sulfamethoxazole, sulfanilamide, sulfamethazine, sulfamerazine, 
ampicillin, isoniazid, metronidazole, 7-ADCA and 7-AVCA were coupled with some 
of the NSAIDs, including ibuprofen, flurbiprofen and aspirin. Four different methods 
were used for these synthesis, which involved preparation of acid chlorides by use of 
thionyl chloride (A20, A24, A25) and oxalyl chloride (A2-A14, A16-A18), use of 
DCCI (A1, A15), and direct interaction of the parent drug molecules (A26). The 
synthesized intermediates and final products were characterised by elemental analysis, 
FT-IR, electronic spectroscopy, 1H and 13C NMR, ESI-MS and single crystal XRD. 
The products were subjected to toxicity study, in vitro anti-bacterial testing, enzyme 
inhibition assays against 5-LOX, AChE, BChE and α-chymotrypsin, and anti-oxidant 
assay. The drug-like ADME properties were computed and the validity of these was 
verified by reliability index (RI) and by comparing the computed values with the 
experimental values from literature.  
3.1. Synthesis 
The NSAIDs selected for this study except benzydamine HCl contained a carboxylic 
acid group. The antibacterial drugs used, belong to different classes and all contained 
at least a primary amino group, except metronidazole. No one synthetic method was 
found to be suitable for synthesis of all the end products. So each synthesis is 
discussed separately. 
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3.1.1. Synthesis of benzydaminium cefazolinate  
When cefazolin sodium and benzydamine HCl were mixed and stirred together in 
water at room temperature, a quaternary ammonium salt of the two molecules was 
formed, in good yield, through mutual neutralization reaction (Scheme 1). The 
crystalline compound was completely characterized by elemental analysis, 
spectroscopic data and single crystal XRD analysis.  
The elemental analysis and ESI-MS results correspond to the proposed composition. 
In the FT-IR spectrum of the compound all the absorption bands due to cefazolin and 
benzydamine were present.  
 Scheme 1. Synthesis of benzydaminium cephazolinate 
In the crystal of the molecular salt, [C19H24N3O]+ [C14H13N8O4S3], the cations and anions are 
linked by NH- - O hydrogen bonds. Short intramolecular CH- - O contacts occur within the 
anion and intermolecular CH---O and C—H- - π bonds help to establish the packing (Figure 
1). 
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3.1.2. Synthesis of aspirin prodrugs (A20, A24, A25) 
These prodrugs were synthesized in two steps according to Scheme 2 [106, 107]. In 
first step, aspirin acid chloride was synthesized by reacting aspirin with thionyl 
chloride in the presence of DMF as a catalyst.  The product produced single spot in 
the TLC. The elemental analysis of the purified product gave CHN analysis 
conforming to C9H7O3Cl composition within 0.3% experimental error. The melting 
point and spectral data were comparable with the literature values confirming the 
formation of the acid chloride. The yield was good. 
Synthesis of A20  
Purified A20 was obtained in good yield according to the experimental procedure. 
The FT-IR spectrum of the compound contained all the bands present in the spectra of 
the component drugs with appearance of a new (NH2CO) band at 3230 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
3479 cm-1 due to (NH2) of sulfanilamide. The 1H-NMR spectrum of the compound 
contained all the peaks in the spectra of the component drugs with appearance of a 
new peak at δ 7.85 ppm due to formation of amide group and disappearance of peaks 
of hydroxyl of the COOH group in aspirin at δ 11.95 ppm and proton of the NH2 in 
sulfanilamide at δ 5.76 ppm. In the 13CNMR formation of amide linkage was 
confirmed by shifting of COOH signal at 170.44 ppm to a lower value of 160.8 ppm. 
The elemental analysis and ESI-MS (M+ m/z: 334.35) data conformed to the 
C15H14N2O5S composition.  
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Figure 1: XRD view of benzydaminium cephazolinate 
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Synthesis of A24 
Purified A24 was obtained in good yield according to the experimental procedure. 
The 1H-NMR spectrum of the compound contained all the peaks in the spectra of the 
component drugs with appearance of a new peak at δ 7.80 ppm due to formation of 
amide group and disappearance of peaks of hydroxyl of the COOH group in aspirin 
at δ 11.95 ppm and proton of the NH2 in sulfamethoxazole at δ 6.1 ppm. In the 
13CNMR formation of amide linkage was confirmed by shifting of COOH signal at 
170.44 ppm to a lower value of 160.9 ppm. The elemental analysis and ESI-MS (M+ 
m/z: 415.07) data conformed to the C19H17N3O6S composition.  
Characterization of A25 
Purified A25 was obtained in good yield according to the experimental procedure. 
The FT-IR spectrum of the compound contained all the bands present in the spectra of 
the component drugs with appearance of a new (NH2CO) band at 3182 cm-1 and 
1683 cm-1 due to formation of the prodrug containing amide linkage and 
disappearance of the band at 1720 cm-1 due to (NH2) of sulfamerazine. The 1H-
NMR spectrum of the compound contained all the peaks in the spectra of the 
component drugs with appearance of new a peak at δ 8.1 ppm due to formation of 
amide group and disappearance of peaks of hydroxyl of the COOH group in aspirin 
at δ 11.95 ppm and proton of the NH2 in sulfamerazine at δ 5.98 ppm. In the 
13CNMR formation of amide linkage was confirmed by shifting of COOH signal at 
170.44 ppm to a lower value of 160.96 ppm. The elemental analysis and ESI-MS (M+ 
m/z: 426.0897) data conformed to the C20H18N4O5S composition.  
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Scheme 2- General reaction for synthesis of aspirin prodrugs (A20, A24, A25) 
3.1.3. Synthesis of ibuprofen prodrugs (A2, A3, A4, A5, A10, A11, A12, A18) 
These prodrugs were synthesized in two steps according to Scheme 3 [108]. In first 
step, ibuprofen acid chloride was synthesized by reacting ibuprofen with oxalyl 
chloride in the presence of DMF as a catalyst.  The product produced single spot in 
the TLC. The elemental analysis of the purified product gave CHN analysis 
conforming to C13H17OCl composition within 0.3% experimental error. The spectral 
data were comparable with the literature values confirming the formation of the acid 
chloride. The yield was good.  
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Scheme 3: synthesis of ibuprofen prodrugs A2, A3, A4, A5, A10, A11, A12, A18 
Synthesis of A2 
Purified A2 was obtained in good yield according to the experimental procedure. The 
FT-IR spectrum of the compound contained all the bands present in the spectra of the 
component drugs with appearance of a new (NH2CO) band at 3334 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
3443 cm-1 due to (NH2) of sulfamethazine. The 1H-NMR spectrum of the 
compound contained all the peaks in the spectra of the component drugs with 
appearance of new a peak at δ 8.2 ppm due to formation of amide group and 
disappearance of peaks of hydroxyl of the COOH group in ibuprofen at δ 11.6 ppm 
and proton of the NH2 in sulfamethazine at δ 5.98 ppm. In the 13CNMR formation of 
amide linkage was confirmed by shifting of COOH signal at 178 ppm to a lower 
value of 172.2 ppm. The elemental analysis and ESI-MS (M+ m/z: 466) data 
conformed to the C25H30N4O3S composition, 
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Synthesis of A3 
Purified A3 was obtained in good yield according to the experimental procedure. The 
FT-IR spectrum of the compound contained all the bands present in the spectra of the 
component drugs with appearance of a new (NHCO) band at 3283 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
3462 cm-1due to (NH2) of sulfanilamide. The 1H-NMR spectrum of the compound 
contained all the peaks in the spectra of the component drugs with appearance of new 
a peak at δ 8.22 ppm due to formation of amide group and disappearance of peaks of 
hydroxyl of the COOH group in ibuprofen at δ 11.6 ppm and proton of the NH2 in 
sulfanilamide at δ 6.86 ppm. In the 13CNMR formation of amide linkage was 
confirmed by shifting of COOH signal at 178 ppm to a lower value of 173 ppm. The 
elemental analysis and ESI-MS (M+ m/z: 360) data conformed to the C19H24N2O3S 
composition. 
Synthesis of A4 
Purified A4 was obtained in good yield according to the experimental procedure. The 
FT-IR spectrum of the compound contained all the bands present in the spectra of the 
component drugs with appearance of a new (NHCO) band at 3337 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
3430 cm-1 due to (NH2) of isoniazid. The 1H-NMR spectrum of the compound 
contained all the peaks in the spectra of the component drugs with appearance of new 
a peak at δ 8.9 ppm due to formation of amide group and disappearance of peaks of 
hydroxyl of the COOH group in ibuprofen at δ 11.6 ppm and proton of the NH2 in 
isoniazid at δ 4.64 ppm. In the 13CNMR formation of amide linkage was confirmed by 
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shifting of COOH signal at 178 ppm to a lower value of 168.8 ppm. The elemental 
analysis and ESI-MS (M+ m/z: 325) data conformed to the C19H23N3O2 composition. 
Synthesis of A5 
Purified A5 was obtained in good yield according to the experimental procedure. The 
FT-IR spectrum of the compound contained all the bands present in the spectra of the 
component drugs with appearance of a new (NHCO) band at 3219 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
3442 cm-1 due to (NH2) of sulfamethoxazole. The 1H-NMR spectrum of the 
compound contained all the peaks in the spectra of the component drugs with 
appearance of new a peak at δ 7.9 ppm due to formation of amide group and 
disappearance of peaks of hydroxyl of the COOH group in ibuprofen at δ 11.6 ppm 
and proton of the NH2 in sulfamethoxazole at δ 6.1 ppm. In the 13CNMR formation 
of amide linkage was confirmed by shifting of COOH signal at 178 ppm to a lower 
value of 169.4 ppm. The elemental analysis and ESI-MS (M+ m/z: 441) data 
conformed to the C23H27N3O4S composition. 
Synthesis of A10 
Purified A10 was obtained in good yield according to the experimental procedure. 
The FT-IR spectrum of the compound contained all the bands present in the spectra of 
the component drugs with appearance of a new (NHCO) band at 1678 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
3400 cm-1 due to (NH2) of sulfamerazine. The 1H-NMR spectrum of the compound 
contained all the peaks in the spectra of the component drugs with appearance of new 
a peak at δ 7.6 ppm due to formation of amide group and disappearance of peaks of 
hydroxyl of the COOH group in ibuprofen at δ 11.6 ppm and proton of the NH2 in 
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sulfamerazine at δ 5.98 ppm. In the 13CNMR formation of amide linkage was 
confirmed by shifting of COOH signal at 178 ppm to a lower value of 172.9 ppm. 
The elemental analysis and ESI-MS (M+ m/z: 452.57) data conformed to the 
C24H28N4O3S composition.  
Synthesis of A11 
Purified A11 was obtained in good yield according to the experimental procedure. 
The FT-IR spectrum of the compound contained all the bands present in the spectra of 
the component drugs with appearance of a new (COOC) band at 1734 cm-1 due to 
formation of the prodrug containing ester linkage and disappearance of the band at 
3836 cm-1 & 1189 cm-1 due to (OH) of metronidazole. The typical spectrum is 
shown in Figure 2(a). The 1H-NMR spectrum of the compound contained all the 
peaks in the spectra of the component drugs with disappearance of peaks of hydroxyl 
of the COOH group in ibuprofen at δ 11.6 ppm and proton of the OH in 
metronidazole at δ 5.03 ppm. The typical spectrum is shown in Figure 2(b). In the 
13CNMR formation of ester linkage was confirmed by shifting of COOH signal at 
178 ppm to a lower value of 174.5 ppm. The typical spectrum is shown in Figure 2(c). 
The elemental analysis and ESI-MS (M+ m/z: 359.42) data conformed to the 
C19H25N3O4 composition. The typical spectrum is shown in Figure 2(d). 
Synthesis of A12 
Purified A12 was obtained in good yield according to the experimental procedure. 
The FT-IR spectrum of the compound contained all the bands present in the spectra of 
the component drugs with appearance of a new (NHCO) band at 3400 cm-1 due to 
formation of the prodrug containing amide linkage.  
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Figure 2(a) Figure 2(b) 
 
Figure 2(c) 
 
Figure 2(d) 
Figure 2: FTIR, H-NHR, C13-NMR and ESI-MS spectra of A11. 
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The 1H-NMR spectrum of the compound contained all the peaks in the spectra of the 
component drugs with appearance of new a peak at δ 7.6 ppm due to formation of 
amide group and disappearance of peaks of hydroxyl of the COOH group in 
ibuprofen at δ 11.6 ppm and proton of the NH2 in 7-ADCA at δ 5.11 ppm. In the 
13CNMR formation of amide linkage was confirmed by shifting of COOH signal at 
178 ppm to a lower value of 171.8 ppm. . The elemental analysis and ESI-MS (M+ 
m/z: 415.16) data conformed to the C22H26N2O4S composition.  
Synthesis of A18 
Purified A18 was obtained in good yield according to the experimental procedure. 
The FT-IR spectrum of the compound contained all the bands present in the spectra of 
the component drugs with appearance of a new (NHCO) band at 3270 cm-1 due to 
formation of the prodrug containing amide linkage. The 1H-NMR spectrum of the 
compound contained all the peaks in the spectra of the component drugs with 
appearance of new a peak at δ 87.6 ppm due to formation of amide group and 
disappearance of peaks of hydroxyl of the COOH group in ibuprofen at δ 11.6 ppm 
and proton of the NH2 in 7-AVCA at δ 5.11 ppm. In the 13CNMR formation of 
amide linkage was confirmed by shifting of COOH signal at 178 ppm to a lower 
value of 171.8 ppm. The elemental analysis and ESI-MS conformed molecular ion 
peak at m/z 415.16 and also the molecular formula C22H26N2O4S.  
3.1.4. Synthesis of flurbiprofen prodrugs (A6, A7, A8, A9, A13, A14, A16, 
A17) 
These prodrugs were synthesized in two steps according to Scheme 4 [109]. In first 
step, flurbiprofen acid chloride was synthesized by reacting flurbiprofen with oxalyl 
chloride in the presence of DMF as a catalyst.  The product produced single spot in 
the TLC. The elemental analysis of the purified product gave CHN analysis 
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conforming to C15H12FOCl composition within 0.3% experimental error. The yield 
was good. Steps for the general reaction are shown in scheme 3. 
 
Scheme 4: synthesis of prodrugs of flurbiprofen (A6, A7, A8, A9, A13, A14, A16, 
and A17) 
Synthesis of A6 
Purified A6 was obtained in good yield according to the experimental procedure. The 
FT-IR spectrum of the compound contained all the bands present in the spectra of the 
component drugs with appearance of a new (NHCO) band at 1583 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
1710 cm-1 due to (NH2) of sulfanilamide. The 1H-NMR spectrum of the compound 
contained all the peaks in the spectra of the component drugs with appearance of new 
a peak at δ 8.2 ppm due to formation of amide group and disappearance of peaks of 
hydroxyl of the COOH group in ibuprofen at δ 11.6 ppm and proton of the NH2 in 
sulfanilamide at δ 6.86 ppm. In the 13CNMR formation of amide linkage was 
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confirmed by shifting of COOH signal at 178 ppm to a lower value of 172.25 ppm. 
The elemental analysis and ESI-MS (M+ m/z: 398) data conformed to the 
C21H19FN2O3S composition.  
Synthesis of A7 
Purified A7 was obtained in good yield according to the experimental procedure. The 
FT-IR spectrum of the compound contained all the bands present in the spectra of the 
component drugs with appearance of a new (NHCO) band at 3251 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
1710 cm-1 due to (NH2) of sulfamerazine. The 1H-NMR spectrum of the compound 
contained all the peaks in the spectra of the component drugs with appearance of new 
a peak at δ 9.2 ppm due to formation of amide group and disappearance of peaks of 
hydroxyl of the COOH group in flurbiprofen at δ 11.6 ppm and proton of the NH2 
in sulfamerazine at δ 5.98 ppm. In the 13CNMR formation of amide linkage was 
confirmed by shifting of COOH signal at 178 ppm to a lower value of 172.2 ppm. 
The elemental analysis and ESI-MS (M+ m/z: 490) data conformed to the 
C26H23FN4O3S composition.  
Synthesis of A8 
Purified A8 was obtained in good yield according to the experimental procedure. The 
FT-IR spectrum of the compound contained all the bands present in the spectra of the 
component drugs with appearance of new bands at 3334cm-1 due to formation of the 
prodrug containing amide linkage and disappearance of bands at 1710 cm-1 due to 
reaction of carboxylic group to produce amide linkage. The 1H-NMR spectrum of the 
compound showed all the peaks present in the spectra of the component drugs with 
appearance of new peak at δ 7.98 ppm due to formation of amide group and 
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disappearance of peaks of hydroxyl group of the COOH (in flurbiprofen) at δ 12.19 
ppm and proton of the NH2 (in sulfamethazine) at δ 5.98 ppm as these protons were 
taken part in the amide formation reaction. CONH is at position C1ʹʹ and was proved 
by shifting of 13C signal to a lower value from180.7 ppm to 172.4 ppm. The elemental 
analysis and ESI-MS (M+ m/z: 504) data conformed to the C27H25FN4O3S. 
Synthesis of A9 
Purified A9 was obtained in good yield according to the experimental procedure. The 
FT-IR spectrum of the compound contained all the bands present in the spectra of the 
component drugs with appearance of a new (NHCO) band at 1595 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
1710 cm-1 due to (NH2) of isoniazid. The 1H-NMR spectrum of the compound 
contained all the peaks in the spectra of the component drugs with appearance of new 
a peak at δ 8.2 ppm due to formation of amide group and disappearance of peaks of 
hydroxyl of the COOH group in flurbiprofen at δ 11.6 ppm and proton of the NH2 
in isoniazid at δ 4.64 ppm. In the 13CNMR formation of amide linkage was confirmed 
by shifting of COOH signal at 180.7 ppm to a lower value of 178 ppm. The 
elemental analysis and ESI-MS conformed The ESI-MS confirmed molecular ion 
peak at m/z 364 and also the molecular formula C21H18FN3O2.  
Synthesis of A13 
Purified A13 was obtained in good yield according to the experimental procedure. 
The FT-IR spectrum of the compound contained all the bands present in the spectra of 
the component drugs with appearance of a new (COOC) band at 1737 cm-1 due to 
formation of the prodrug containing ester linkage. The 1H-NMR spectrum of the 
compound contained all the peaks in the spectra of the component drugs with 
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disappearance of peaks of hydroxyl of the COOH group in flurbiprofen at δ 11.6 
ppm and proton of the OH in metronidazole at δ 5.03 ppm. In the 13CNMR 
formation of ester linkage was confirmed by shifting of COOH signal at 180.7 ppm 
to a lower value of 172.6 ppm. The elemental analysis and ESI-MS (M+ m/z: 397) 
data conformed to the C21H20FN3O4. 
Synthesis of A14 
Purified A14 was obtained in good yield according to the experimental procedure. 
The FT-IR spectrum of the compound contained all the bands present in the spectra of 
the component drugs with appearance of a new (NHCO) band at 3265 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
1710 cm-1 due to (NH2) of sulfamethoxazole. The 1H-NMR spectrum of the 
compound contained all the peaks in the spectra of the component drugs with 
appearance of new a peak at δ 8.2 due to formation of amide group and disappearance 
of peaks of hydroxyl of the COOH group in flurbiprofen at δ 11.6 ppm and proton of 
the NH2 in sulfamethoxazole at δ 6.1 ppm. In the 13CNMR formation of amide 
linkage was confirmed by shifting of COOH signal at 180.77 ppm to a lower value 
of 172.4 ppm. The elemental analysis and ESI-MS (M+ m/z: 502) data conformed to 
the C25H22FN3O4S. 
Synthesis of A16 
Purified A16 was obtained in good yield according to the experimental procedure. 
The FT-IR spectrum of the compound contained all the bands present in the spectra of 
the component drugs with appearance of a new (NHCO) band at 1595 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
1710 cm-1due to (NH2) of 7-ADCA. The 1H-NMR spectrum of the compound 
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contained all the peaks in the spectra of the component drugs with appearance of new 
a peak at δ 8.1ppm due to formation of amide group and disappearance of peaks of 
hydroxyl of the COOH group in flurbiprofen at δ 11.6 ppm and proton of the NH2 
in 7-ADCA at δ 5.1 ppm. In the 13CNMR formation of amide linkage was confirmed 
by shifting of COOH signal at 180.77 ppm to a lower value of 172.2 ppm. The 
elemental analysis and ESI-MS (M+ m/z: 440) data conformed to the C23H21FN2O4S. 
Synthesis of A17 
Purified A17 was obtained in good yield according to the experimental procedure. 
The FT-IR spectrum of the compound contained all the bands present in the spectra of 
the component drugs with appearance of a new (NHCO) band at 1595 cm-1 due to 
formation of the prodrug containing amide linkage and disappearance of the band at 
1710 cm-1 due to (NH2) of 7-AVCA. The 1H-NMR spectrum of the compound 
contained all the peaks in the spectra of the component drugs with appearance of new 
a peak at δ 8.1 due to formation of amide group and disappearance of peaks of 
hydroxyl of the COOH group in flurbiprofen at δ 11.6 ppm and proton of the NH2 
in 7-AVCA at δ 5.1 ppm. In the 13CNMR formation of amide linkage was confirmed 
by shifting of COOH signal at 180.77 ppm to a lower value of 172.2 ppm. The 
elemental analysis and ESI-MS conformed molecular ion peak at m/z 451 and also the 
molecular formula C24H21FN2O4S.  
3.1.5. Synthesis of ibuprofen and flurbiprofen prodrugs with ampicillin (A1, 
A15) 
These prodrugs were synthesized in single step reaction according to Scheme [110]. 
In this prodrug was synthesized by reacting ampicillin with ibuprofen/flurbiprofen in 
the presence of DCCI as a catalyst.  The product produced single spot in the TLC. The 
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elemental analysis of the purified product gave CHN analysis conforming to 
molecular composition of both products within 0.3% experimental error.  
 
Scheme 5: synthesis of prodrugs of ampicillin (A1, A15) 
Synthesis of A1 
Purified A1 was obtained in good yield according to the experimental procedure. The 
FT-IR spectrum of the compound contained all the bands present in the spectra of the 
component drugs with appearance of new bands at1519 cm-1 due to formation of the 
prodrug containing amide linkage and disappearance of bands at 1710 cm-1 due to 
reaction of carboxylic group to produce amide linkage. The 1HNMR spectrum of the 
compound showed all the peaks present in the spectra of the component drugs with 
appearance of new peak at δ 8.1 ppm due to formation of amide group and 
disappearance of peaks of hydroxyl group of the COOH (in flurbiprofen) at δ 11.95 
ppm and proton of the NH2 (in ampicillin) at δ 5.42 ppm as these protons were taking 
part in the amide formation. In the 13CNMR the CONH signal at 178 ppm shifted to 
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a lower value of 176 ppm. The elemental analysis and ESI-MS (M+ m/z: 559) data 
conformed to the C29H34N3NaO5S. 
Synthesis of A15 
Purified A15 was obtained in good yield according to the experimental procedure. 
The FT-IR spectrum of the compound contained all the bands present in the spectra of 
the component drugs with appearance of new bands at 3244 cm-1 due to formation of 
the prodrug containing amide linkage and disappearance of bands at 1710 cm-1 due to 
reaction of carboxylic group to produce amide linkage. The 1H-NMR spectrum of the 
compound showed all the peaks present in the spectra of the component drugs with 
appearance of new peak at δ 8.2ppm due to formation of amide group and 
disappearance of peaks of hydroxyl group of the COOH (in flurbiprofen) at δ 12.19 
ppm and proton of the NH2 (in ampicillin) at δ 5.42 ppm as these protons were taken 
part in the amide formation reaction.  CONH is at position 1ʹʹ and was proved by 
shifting of 13C signal to a lower value from180.77 ppm to172.2 ppm. The elemental 
analysis and ESI-MS (M+ m/z: 597) data conformed to the C31H29FN3NaO5S. 
3.2. Biological activities  
Biological activities of the prodrugs were studied by determining their anti-bacterial 
and enzyme inhibition activities. The results are discussed as follows. 
3.2.1. Antibacterial activities 
 The results are given in Table 8. All the products inhibited the growth of different 
organisms to variable extents. Results indicated that in parent drugs, only 
sulfamerazine and ampicillin showed better inhibition zones against E. coli. In other 
cases all the products, along with prodrugs of these two antibiotics showed better 
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zones of inhibition as compared to standard antibiotics used. Flurbiprofen prodrugs 
(A6, A7, A16, A17, and A18) were found to be more active than aspirin prodrugs 
which in turn were more active than ibuprofen prodrugs. Similar trend was observed 
for S. aureus. Results of prodrugs of ampicillin, sulfamethazine, isoniazid, 
metronidazole sulfamethoxazole were positive against S.aureus. The prodrugs A3, 
A16 and A25 exhibited activities similar to the parent drugs against S. aureus. 
Compounds derived from 7-AVCA showed highest activities against E. coli S. 
aureus. Nearly all the synthesized prodrugs inhibited the growth of both Gram-
positive and Gram-negative bacteria, showing their broad spectrum activity. The 
prodrugs did not show significant activities against Bacillus thuringenesis. Moderate 
activities were shown by all the prodrugs against Bacillus amyliquefaciens and 
enhanced activities were observed against Bacillus licheniformis as compared with 
those of the parent antibiotics except for A3, A10 and A17.  
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Table 7: Antibacterial activity of standard drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound E. coil 
 
S. aureus  Bacillus 
subtillis 
Bacillus 
amyliquefaciens 
Bacillus 
licheniformis 
Bacillus 
thuringenesis 
10 g/ well Zone of Inhibition (mm) 
Metronidazole - - 17 - 8 12 
Sulfamethazine - 25 - - - 15 
Sulamerazine 28 24 - - - 15 
Isoniazid - 15 - - 12 10 
Sulfamthoxazole - 38 - 13 - 16 
7-ADCA - - 10 - 10 25 
7-AVCA - 26 - - - 10 
Sulfanilamide - - 9 20 11 18 
Ampilicin 50 48 22 13 11 - 
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Table 8: Antibacterial activity of prodrugs 
Compound E. coil 
 
S. aureus  
 
Bacillus 
subtillis 
Bacillus 
amyliquefaciens 
Bacillus 
licheniformis 
Bacillus 
thuringenesis 
10 µg/ well Zone of inhibition (mm) 
A1 18 11 18 13 13 19 
A2 19 21 23 - 18 18 
A3 - - 11 15 - 10 
A4 21 20 25 19 25 18 
A5 16 17 20 21 14 22 
A6 22 23 12 19 12 - 
A7 19 21 18 - 21 22 
A8 20 28 22 21 19 - 
A9 20 24 24 - 15 18 
A10 22 21 - 10 - 20 
A11 12 - 20 - 20 - 
A12 20 28 20 - 20 - 
A13 14 16 22 10 14 - 
A14 - 23 15 12 15 - 
A15 20 18 18 - 15 15 
A16 15 - 12 - 24 25 
A17 37 36 - 12 - 25 
A18 42 40 - - 26 22 
A20 18 21 15 17 20 - 
A24 - 29 - 20 18 23 
A25 20 - 16 22 22 25 
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3.2.2. Enzyme inhibition studies 
Anti-inflammatory assay for the synthesized prodrugs 
Anti-inflammatory activity of the prodrugs was determined in vitro by enzyme 
inhibition assays as it was the other expected function of the product. The prodrugs 
exhibited better anti-inflammatory effect as compared with the parent NSAIDs (Table 
9). Prodrugs were assayed for their inhibition against 5-LOX. The inhibition of the 
enzyme by ibuprofen was 42.51±0.12 % while its prodrugs (A1, A2, A10, A11, A12, 
A18), exhibited better activities (Table 10).  
AI activity of flurbiprofen was 95.81±0.16 %; whereas, its prodrugs exhibited 
significant activities but lesser than the parent drug. AI activity of aspirin was 
38.45±0.13 % and its prodrugs exhibited enhanced activities. The activities of A20, 
A24 and A25 were 2, 2.5 and 3 times more active than the aspirin, respectively. 
Acetylcholinesterase assay  
AChE inhibition assay was performed for all the synthesized prodrugs and was 
compared with the parent drugs (ibuprofen, flurbiprofen, and aspirin). The 
compounds A1, A2, A5, A6, A7, A8, A9, A15, A16, A18, and A24 exhibited 
excellent inhibitory activities and better than all the parent drugs (Table 11 and Table 
12). 
Butyrylcholinesterase assay 
Prodrugs synthesized from ibuprofen, flurbiprofen and aspirin exhibited better results 
than all the three parent drugs (Table 13 and Table 14). These results are encouraging 
and can address the issue of dementia. 
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Table 9: Anti-Inflammatory assay - standards 
Anti-
inflammatory 
drug 
Concentration 
of the solution 
used in assay 
(mM) 
Inhibition 
(%) 
IC50 
(μmol) 
Ibuprofen 
0.5 42.51±0.12 _ 
Flurbiprofen 
0.5 95.81±0.16 50.51±0.14 
Aspirin 
0.5 38.45±0.13 _ 
Baicalein 
0.5 93.79±1.27 22.4±1.3 
 
Table 10: Anti-Inflammatory activity - prodrugs 
Sample name Concentration 
of the solution 
used in assay 
(mM) 
Inhibition 
(%) 
IC50 
(μmol) 
A1 0.5 
48.45±0.11  
A2 
0.5 43.31±0.17  
A3 
0.5 48.37±0.14  
A4 
0.5 49.63±0.15  
A5 
0.5 40.41±0.16  
A6 
0.5 95.74±0.11  
A7 
0.5 83.72±0.19  
A8 
0.5 90.21±0.13  
A9 
0.5 75.21±0.16  
A10 
0.5 89.05±0.15 58.21±0.04 
A11 
0.5 46.43±0.14 _ 
A12 
0.5 47.67±0.61 _ 
A13 
0.5 55.72±0.12 <400 
A14 
0.5 36.24±0.17 - 
A15 
0.5 45.45±0.12 _ 
A16 
0.5 68.41±0.18 111.21±0.11 
A17 
0.5 42.73±0.17 _ 
A18 
0.5 58.33±0.13 234.51±0.05 
A20 
0.5 70.67±0.15 107.38±0.17 
A24 
0.5 78.11±0.13 91.25±0.16 
A25 
0.5 94.09±0.11 52.61±0.0.5 
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Table 11: Acetylcholinesterase assay of standards 
Drugs used as 
standard 
 
Concentration 
of the solution 
used in assay 
(mM) 
Inhibition 
(%) 
IC50 
(μmol) 
Ibuprofen 
0.5 61.19±0.04 235.11±0.17 
Flurbiprofen 
0.5 31.43±0.05 50.51±0.14 
Aspirin 
0.5 49.59±0.11 <400 
Eserine 
0.25 91.29±1.17 0.04±0.0001 
Table 12: Acetylcholinesterase assay of prodrugs 
Prodrug code Concentration 
of the solution 
used in assay 
(mM) 
Inhibition 
(%) 
IC50 
(μmol) 
A1 
0.5 71.95±0.22 143.61±0.04 
A2 
0.5 74.27±0.32 138.41±0.11 
A3 
0.5 47.21±0.11 <600 
A4 
0.5 56.39±0.76 <400 
A5 
0.5 85.31±0.88 81.61±0.17 
A6 
0.5 69.05±0.19 201.21±0.17 
A7 
0.5 70.15±0.78 198.65±0.25 
A8 
0.5 72.34±0.43 139.51±0.21 
A9 
0.5 78.92±0.24 112.11±0.14 
A10 
0.5 66.73±0.62 219.41±0.04 
A11 
0.5 63.83±0.35 223.11±0.01 
A12 
0.5 67.51±0.33 196.31±0.03 
A13 
0.5 63.83±0.68 251.23±0.22 
A14 
0.5 50.21±0.58 <400 
A15 
0.5 73.69±0.98 127.31±0.11 
A16 
0.5 71.48±0.56 126.91±0.11 
A17 
0.5 69.65±0.36 131.25±0.14 
A18 
0.5 71.39±0.21 125.21±0.05 
A20 
0.5 44.94±0.14 <600 
A24 
0.5 72.39±0.16 115.71±0.16 
A25 
0.5 47.11±0.18 <600 
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Table 13: Butyrylcholinesterase assay of standards 
Anti-
inflammatory 
drug 
Concentration 
of the solution 
used in assay 
(mM) 
Inhibition 
(%) 
IC50 
(μmol) 
Ibuprofen 
0.5 35.51±0.15 <600 
Flurbiprofen 
0.5 36.17±0.24 <600 
Aspirin 
0.5 19.91±0.19 <600 
Eserine 
0.25 82.82±1.09 0.85±0.0001 
Table 14: Butyrylcholinesterase assay of prodrugs  
Prodrugs code Concentration 
of the solution 
used in assay 
(mM) 
Inhibition 
(%) 
IC50 
(μmol) 
A1 
0.5 77.57±0.19 78.81±0.01 
A2 
0.5 79.81±0.26 67.23±0.11 
A3 
0.5 65.88±0.36 214.41±0.05 
A4 
0.5 53.67±0.77 301.21±0.17 
A5 
0.5 76.18±0.25 118.91±0.08 
A6 
0.5 78.49±0.17 75.41±0.16 
A7 
0.5 78.53±0.39 73.61±0.22 
A8 
0.5 58.69±0.45 269.91±0.21 
A9 
0.5 61.25±0.85 238.51±0.11 
A10 
0.5 46.57±0.35 <500 
A11 
0.5 68.11±0.15 164.11±0.51 
A12 
0.5 69.57±0.33 149.11±0.18 
A13 
0.5 73.13±0.28 142.11±0.22 
A14 
0.5 69.71±0.45 156.71±0.18 
A15 
0.5 57.59±0.68 288.21±0.11 
A16 
0.5 54.83±0.21 <400 
A17 
0.5 63.15±0.33 221.61±0.14 
A18 
0.5 57.81±0.55 281.51±0.16 
A20 
0.5 84.24±0.32 45.11±0.21 
A24 
0.5 78.46±0.62 126.11±0.16 
A25 
0.5 68.11±0.21 142.71±0.15 
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DPPH Activity 
In our results inhibition (%) by A4 (55.65) was highest in all the reactants and 
prodrugs, while A9 revealed the lowest % scavenging value (5.67). The assay 
regarding reduction capability of DPPH radicals on reacting with prodrugs was 
determined as a function of their concentration by the decrease in absorbance at 517 
nm (DPPH). There is significant decrease in the concentration of DPPH radical due to 
the scavenging ability of prodrug solution. Table shows a sharp fall in the absorbance 
of DPPH in the prodrug A3, A4, A5, A6, A7, A11, A12, A13, A15, A17, A18, A20, 
A24, and A25. In comparison of prodrugs of ibuprofen with ibuprofen, A3, A4, A11, 
A12, and A18 showed enhanced performance than the parent drug. A6, A7, A8, A13, 
A15, A16, and A17 exhibited improved results than the parent drug flurbiprofen. All 
the aspirin’s prodrugs (A20, A24, and A25) were better in inhibition than aspirin 
(Table 15 and Table 16). 
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Table 15: DPPH activity of standards  
Anti-
inflammatory 
drug 
 
Concentration 
of the solution 
used in assay 
(mM) 
Inhibition 
(%) 
IC50 
(μmol) 
Ibuprofen 
0.5 11.33±0.11 <500 
Flurbiprofen 
0.5 6.37±0.22 <500 
Aspirin 
0.5 10.87±0.17 <500 
Quercetin 0.25 93.21±0.97 16.96±0.14 
 
Table 16: DPPH activity of prodrugs 
Prodrug code Concentration 
of the solution 
used in assay 
(mM) 
Inhibition 
(%) 
IC50 
(μmol) 
A1 0.5 7.92±0.39 <500 
A2 0.5 6.57±0.92 <500 
A3 0.5 20.81±0.48 <500 
A4 0.5 55.65±0.38 <500 
A5 0.5 10.59±0.22 <500 
A6 0.5 15.15± 0.87 <500 
A7 0.5 12.85±0.98 <500 
A8 0.5 8.66±0.56 <500 
A9 0.5 5.67±0.89 <500 
A10 0.5 7.64±0.37 <500 
A11 0.5 12.48±0.11 <500 
A12 0.5 16.38±0.67 <500 
A13 0.5 11.62±0.27 <500 
A14 0.5 6.03±0.16 <500 
A15 0.5 17.11±0.58 <500 
A16 0.5 13.55±0.62 <500 
A17 0.5 23.69±0.37 <500 
A18 0.5 16.87±0.29 <500 
A20 0.5 14.49±0.55 <500 
A24 0.5 14.16±0.66 <500 
A25 0.5 14.37±0.31 <500 
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3.2.3. Anti-tuberculosis activity 
For getting the results for anti-tuberculosis activity, slants were observed carefully 
after 6 weeks of incubation according to the guide lines by W.H.O. Relative growth of 
an inoculum on a drug free controlled medium was compared (Figure 3) with any 
growth on culture media containing isoniazid, A4 and A9 in Figure 4, Figure 5 and 
Figure 6 respectively.  No bacterial colonies were grown and observed on the culture 
media in the tubes containing the drugs while a good number of colonies were 
observed in drug free tube. It clearly indicated that new prodrugs synthesized have 
positive anti-tuberculosis activity. Mycobacterium tuberculosis bacteria were sensitive 
towards isoniazid and both the mutual prodrugs. 
 
Figure 3: Mycobacterial colonies in drug free tube 
 
 Figure 4: No Mycobacterial colonies in the tube containing isoniazid 
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Figure 5: No Mycobacterial colonies in the tube containing A4 
 
Figure 6: No Mycobacterial colonies in the tube containing A9 
 
Table 17: Anti-tuberculosis activity of the standard & prodrug 
Obs. no.   
Compounds Anti-tuberculosis activity 
1 
Isoniazid +ve 
2 
A4 +ve 
3 
A9 +ve 
3.2.4. Toxicity  
Acute toxicity 
For observing any possible toxic effects of synthesized mutual prodrugs on mice, 
these were carefully looked after and monitored, after giving dose, for 14 days. 
According to the OCED guidelines [120], some very important points were very 
carefully monitored, as these were important for deciding the acute toxicity of the 
drugs and prodrugs. These points are listed in the table 18. 
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Table 18: Important points regarding toxic effects in mice 
 
Important factors regarding toxicity Responses 
Condition of the fur  Found normal 
 Skin  Found normal 
 Subcutaneous swellings  No swelling 
 Abdominal distension Nil 
 Eyes dullness  Nil 
 Eyes  opacities  Normal 
 Pupil diameter  Nil 
 Ptosis  Normal 
Colour and consistency of the faeces  Normal 
Wetness or soiling of the perineum  No 
Condition of teeth  Found normal 
Breathing abnormalities  Found normal 
Gait  Found normal 
Behaviour pattern Found normal 
Sleep Slightly disturbed 
first day and then 
remained normal 
for rest of 13 days 
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Mice showed anxiety and distress after dosing for first half an hour but they got 
normal within first 4 hours after dosing. It was recorded that all these physical 
characters were detected to be normal in rest of all the days. All these above 
mentioned Conditions were observed for the signs of any possible toxicity after giving 
dose to mice, but there were no such symptoms. No toxic effects were observed in 
mice. 
Mortality was the key criteria in assessing the acute toxicity (LD50) of any drug. In 14 
days there was no mortality recorded. The administration of the prodrugs did not 
show any significant changes in the body weight, indicating that it did not have 
adverse effects on body weight. 
Sub-chronic toxicity test 
Mice were observed carefully for the first seven days periodically twice a day and 
then on daily basis at the same time. Clinical observations were done prior to the first 
dose and then on weekly basis. There was slow but constant increase in the body 
weight during these 90 days indicated prodrugs did not produce any undesirable 
effects on the physiology of the mice. Consumption of food and water was slightly 
decreased during last 30 days.  At the end of 90 days administration of drugs, the liver 
and stomach tissues were removed from mice and then were stored in 10% formalin. 
5μm thick paraffin sections of these tissues were prepared stained with haematoxylin 
and eosin dye. These sections were studied for histopathological changes.  The control 
group showed normal cellular architecture with well-presented cytoplasm and intact 
nucleus (Figure 7). The liver sections of drug treated mice (group II) showed hepatic 
cells with variable toxicity characterized by different levels of disarrangement and 
degeneration of hepatic cells. Mouse treated with ibuprofen showed granular 
cytoplasm along with cellular swelling. Nucleus also showed fragmentations (Figure 
8). Mouse treated with flurbiprofen showed shrunken hepatic cords. Sinusoidal spaces 
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have become increased (Figure 9). Mouse treated with aspirin showed cellular 
swelling along with hydropic degeneration (Figure 10). Mouse treated with 
metronidazole cellular swelling along with change in cytoplasmic components (Figure 
11). In sulfanilamide treated mouse granular cytoplasmic with increased sinusoidal 
spaces are visible (Figure 12). Mouse treated with sulfamethoxazole hydropic 
degeneration where nucleus was seen in normal condition (Figure 13). 
The liver sections of mouse treated with prodrugs (group-III) showed lesser 
disarrangements and degeneration of hepatocytes. Sinusoidal spaces have sinusoidal 
capillaries and have few RBCs. The hepatocytes are less swollen and have some 
vacuoles. In some areas central veins can be seen to be congested. Nucleus can be 
seen normal in all these slides although very slight cytoplasmic swelling can be seen 
in some places (Fig 14-20). 
96 
 
 
Figure 7: Section of the liver of the mouse of control group 
 
Figure 8: Section of the liver of mouse treated with ibuprofen 
 
 
Figure 9: Section of the liver of the mouse treated with Flurbiprofen 
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Figure 10: Section of the liver of the mouse treated with aspirin 
 
Figure 11: Section of the liver of moue treated with metronidazole 
 
 
Figure 12: Section of the liver of mouse treated with sulfanilamide 
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Figure 132: Section of the liver of the mouse treated with sulfamethoxazole 
 
Figure 14: Section of the liver of the mouse treated with A5 
 
Figure 15: Section of the liver of the mouse treated with A6 
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Figure 16: Section of the liver of the mouse treated with A11 
 
Figure 17: Section of the liver of the mouse treated with A13 
 
 
Figure 18: Section of the liver of the mouse treated with A14 
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Figure 19: Section of the liver of the mouse treated with A20 
 
 
Figure 20: Section of the liver of the mouse treated with A24 
3.3. Computational studies 
Some of the physico-chemical properties like molar refractivity, molar volume, 
parachor, index of refraction, surface tension, density and polarizability were 
predicted using ACD/ilabs2. By using these predictions, a good set of database 
regarding compound was managed. These calculations were done for facilitating the 
further experimental designs by comparing the actual results with predicted ones. 
Structure related properties were also determined to help in quantitative structure 
activity relationship (Table 19 and Table 20). These in computational studies also 
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helped to predict the behaviour of the drug in vivo, for example Log BB, Log PS and 
bioavailability values (Table 21). One advantage of using these in computational 
studies was the detail about structure, physical, chemical and biological properties 
which were not possible. These reliable predictions results in increased speed of 
experiments. Another advantage of these studies is the reduction in animal and 
reagent use. 
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Table 19: Computational predicted physico-chemical properties of the synthesized prodrugs 
Prodrug  Molar 
refractivity   
(cm3) 
Molar 
volume  
(cm3) 
Parachor 
(cm3) 
Index of 
refraction 
Surface 
tension 
(dyne/cm) 
Density 
(g/cm3) 
Polarizability 
(×10-24 cm3) 
A1 147.16±0.4 412.3±5.0 1154.8±0.03 1.632±0.03 61.5±5.0 1.30±0.1 58.34±0.5 
A2 129.61±0.4 374.7±3.0 133.1±6.0 1.608±0.02 57.7±3.0 1.244±0.036 51.38±0.5 
A3 100.02±0.4 300.0±3.0 793.1±6.0 1.581±0.02 48.7±3.0 1.201±0.06 39.65±0.5 
A4 94.12±0.3 289.6±3.0 751.5±4.0 1.563±0.02 45.3±3.0 1.123±0.06 37.31±0.5 
A5 119.67±0.4 348.0±3.0 954.5±6.0 1.603±0.02 56.5±3.0 1.268±0.06 47.44±0.5 
A6 106.35±0.4 303.3±3.0 816.0±6.0 1.618±0.02 52.3±3.0 1.313±0.06 42.16±0.5 
A7 131.31±0.4 361.8±3.0 1017.7±6.0 1.645±0.02 62.6±3.0 1.355±0.06 52.05±0.5 
A8 129.61±0.4 374.7±3.0 1033.1±6.0 1.608±0.02 57.7±3.0 1.244±0.06 51.38±0.5 
A9 99.93±0.3 292.8±3.0 778.4±4.0 1.598±0.02 49.8±3.0 1.240±0.06 39.61±0.5s 
A10 124.98±0.4 358.5±3.0 994.8±6.0 1.614±0.02 59.2±3.0 1.262±0.06 49.54±0.5 
A11 99.18±0.5 302.5±7.0 772.4±8.0 1.569±0.05 42.5±7.0 1.18±0.1 39.31±0.5 
103 
 
 
 
 
 
 
A12 108.91±0.4 308.8±5.0 855.3±6.0 1.623±0.03 58.8±5.0 1.30±0.1 43.17±0.5 
A13 106.09±0.5 310.7±7.0 810.0±8.0 1.598±0.05 46.2±7.0 1.27±0.1 42.05±0.5 
A14 125.99±0.4 351.3±3.0 977.4±6.0 1.636±0.02 59.8±3.0 1.364±0.06 49.94±0.5 
A15 153.49±0.4 410.0±5.0 1177.8±6.0 1.671±0.03 68.0±5.0 1.40±0.1 60.84±0.5 
A16 115.23±0.4 306.7±5.0 878.3±6.0 1.674±0.03 67.2±5.0 1.43±0.1 45.68±0.5 
A17 119.63±0.4 318.1±5.0 907.5±6.0 1.675±0.03 66.2±5.0 1.42±0.1 47.42±0.5 
A18 113.31±0.4 320.2±5.0 884.6±6.0 1.625±0.03 58.2±5.0 1.29±0.1 44.92±0.5 
A20 83.40±0.4 293.3±3.0 662.4±6.0 1.613±0.02 58.6±3.0 1.396±0.06 33.06±0.5 
A24 103.05±0.4 287.3±3.0 823.8±6.0 1.636±0.02 67.5±3.0 1.445±0.06 40.85±0.5 
A25 108.36±0.4 297.7±3.0 864.1±6.0 1.648±0.02 70.9±3.0 1.432±0.06 42.96±0.5 
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Table 20: Computational predicted Structure related properties 
Prodrug 
name 
No. of 
hydrogen 
bond donors 
No. of 
hydrogen bond 
acceptor 
TPSA No of 
rotatable 
bonds 
A1 3 8 141.11 9 
A2 2 7 109.43 8 
A3 3 5 97.64 6 
A4 2 5 71.09 6 
A5 2 7 109.68 8 
A6 3 5 97.64 5 
A7 2 7 109.43 7 
A8 2 7 109.43 8 
A9 2 5 71.09 5 
A10 2 7 109.43 8 
A11 0 7 92.95 9 
A12 2 6 112.01 6 
A13 0 7 92.95 8 
A14 2 7 109.68 7 
A15 3 8 141.11 8 
A16 2 6 112.01 5 
A17 2 6 112.01 6 
A18 2 6 112.01 7 
A20 3 7 123.94 5 
A24 2 9 135.98 7 
A25 2 9 135.73 7 
Table 21: Computational predicted LogBB, LogPS and Bioavailability of A1-A25 . 
Prodrug  Log BB LogPS Bioavailability 
A1 0.44 -2.8 Less than 30% 
A2 -1.8 0.28 Between 30-70% 
A3 0.17 -2.5 More than 70% 
A4 0.66 -1.7 More than 70% 
A5 0.17 -2.4 Between 30-70% 
A6 -1.04 -1.7 More than 70% 
A7 -0.94 -1.9 Between 30-70% 
A8 -0.94 -2.5 Between 30-70% 
A9 0.66 -2.5 More than 70% 
A10 -0.07 -1.8 Between 30-70% 
A11 1.18 -1.2 Less than 30% 
A12 -1.05 -2.8 Between 30-70% 
A13 -0.58 -1.1 Less than 30% 
A14 -1.04 -2.5 Between 30-70% 
A15 -0.03 -2.7 Less than 30% 
A16 0.04 -2.6 Between 30-70% 
A17 -0.09 - Less than 30% 
A18 0.13 -2.7 Between 30-70% 
A20 -1.04 -2.3 Between 30-70% 
A24 -1.07 -3.4 Between 30-70% 
A25 -1.02 -2.3 Between 30-70% 
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Lipinski’s rule of five (also known as Pfizer’s rule of five) is a basic criteria to evaluate 
druglikeness which determines if a chemical compound can be used as orally active drug 
in humans. According to the rule [127] a drug molecule should not have more than 5 
hydrogen bond donor and also not more than 10 hydrogen bond acceptors. All the 
synthesized prodrugs follow these two criteria. Third criteria are that molecular mass 
should not be greater than 500 daltons. All the synthesized prodrugs except A1 and A15 
followed this as well. Molar refractivity should be between 40 to130. Prodrugs except 
A1, A15 followed this. Polar surface area of the prodrugs was less than 140 Ǻ2 except A1 
and A15. Bioavailability of majority of the synthesized prodrugs was greater than 70%. A 
drug having 10 or lesser rotatable bonds and polar surface area lesser than 140 Ǻ2 are 
predicted to have good oral bioavailability [128]. Compounds having more than more 
than 0 value of log BB are CNS active compounds [129]. Nearly all the compounds 
except A1, A3, A4, A5, A9, A11, A16 are CNS inactive so these are safe to use as these 
will not penetrate through the blood brain barrier (Table 22).  
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Table 22: Computational predicted LD50 values (mg/kg) of prodrugs 
Prodrug  Mouse  Rat 
Intraperitoneal 
(IP) 
Oral Intravenous Subcutaneous Intraperitoneal Oral  
A2 770  17000 350 1400 960 11000 
A3 610 8600 130 1800 1200 5000 
A4 530 1100 160 650 250 1000 
A5 870 4900 330 1600 2000 11000 
A6 950 5100 130 1700 1200 2000 
A7 1000 8300 340 2400 1300 6900 
A8 770 13000 350 1400 960 11000 
A9 1000 590 100 1000 290 610 
A10 810 17000 380 1500 1100 11000 
A11 790 1900 140 2200 1800 1900 
A12 2300 13000 1600 3400 3100 13000 
A13 1100 1600 130 2600 1900 880 
A14 1100 4000 270 2100 2200 5900 
A16 3700 9000 1300 4100 3000 5500 
A17 3500 8200 1100 3900 3200 4200 
A18 2300 11000 1300 5200 3500 9900 
A20 1100 12000 340 2200 1600 5700 
A24 2200 6300 680 1600 3500 7900 
A25 1400 16000 600 1700 1800 7800 
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3.4. Conclusions 
The mutual prodrugs were successfully synthesized from anti-infectives (ampicillin, 
isoniazid, metronidazole, sulfamethoxazole, sulfamerazine, sulfamethazine, sulfanilamide, 7-
ADCA, 7-AVCA, Cephazolin) and NSAIDs (ibuprofen, flurbiprofen, aspirin, benzydamine). 
These prodrugs were completely characterized by using various analytical techniques 
including electronic spectroscopy, FT-IR, 1H NMR and 13C NMR and single crystal structure 
determination by XRD. The prodrugs were found to be more active and less toxic than the 
parent drugs in various in vitro and in vivo tests. In this work, it has been demonstrated that 
NSAIDs containing carboxylic groups can easily be covalently coupled with anti-infectives 
containing amino groups to produce mutual prodrugs with dual activity and improved toxicity 
profile. 
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